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ABSTRACT 
 
Alpha-synuclein (α-syn) is a protein that becomes aggregated into Lewy bodies and other 
insoluble inclusions in Parkinson’s disease and some other neurodegenerative diseases. Its 
expression is increased also in drug addiction. The principal physiological function of the 
protein appears to be regulation of synaptic dopamine (DA) signaling in the brain, but the 
protein also seems to regulate other neurotransmitter systems and is expressed throughout 
the body. The aim of the current work was to examine the neuromodulatory effects by 
which α-syn influences synaptic signaling in different scenarios. 
The role of α-syn in development of addiction was studied by comparing α-syn protein 
expression between two rat lines bred for differential ethanol preference (study I). The 
ethanol preferring Alko, alcohol rats displayed significantly higher α-syn expression in 
nucleus accumbens core in comparison to their non-ethanol preferring Alko, non-alcohol 
counterparts. Constant potential amperometry (CPA) revealed that the increased α-syn 
expression in the ethanol preferring rats was associated with a decrease in stimulated DA 
overflow and facilitation of re-uptake.  
Possible role of α-syn in peripheral cholinergic signaling and motor control was 
examined with electromyography in wild-type and α-syn knockout mice (study II). Lack of 
α-syn caused dysregulation in the neuromuscular junction, and the α-syn deficient mice 
showed signs of deteriorated motor learning, but displayed no significant defects in muscle 
strength or ambulation.  
The effect of α-syn on general neuronal excitability and the resulting depolarization was 
determined by measuring the initiation and propagation of cortical spreading depression in 
wild-type and α-syn knockout mice using direct current potential recording (study III). 
However, no differences were revealed between the two lines.  
α-Syn can be transferred from neuron to neuron via the extracellular space, but it is not 
known whether exogenous α-syn is able to influence synaptic DA signalling. Therefore α-
syn protein was microinjected into the brain of wild-type and α-syn knockout mice, and the 
effects on DA signaling were measured with CPA (study IV). This revealed that the 
exogenous protein can affect stimulated DA overflow and that the effects depend on the 
presence of endogenous α-syn. 
It can be concluded that α-syn is involved in the fine adjustment of synaptic signalling 
and its main function under normal conditions is to reduce DA release and facilitate its re-
uptake, even though α-syn can have also paradoxical effect on these functions under 
certain conditions. At the behavioral level, this synaptic modulation can affect functions 
such as preference for substances of abuse and motor learning. 
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TIIVISTELMÄ 
 
Alfa-synukleiini (α-syn) on hermopäätteiden valkuaisaine joka kertyy Lewyn kappaleiksi ja 
muiksi liukenemattomiksi kertymiksi Parkinsonin taudissa ja erinäisissä muissa 
hermorappeumataudeissa. α-Syn:n ilmentyminen lisääntyy myös riippuvuudessa. α-Syn:n 
fysiologinen tehtävä vaikuttaisi olevan dopamiini (DA) – välitteisen synaptisen 
signaalinvälityksen säätely aivoissa, mutta se voi vaikuttaa myös muiden 
välittäjäainejärjestelmien toimintaan ja sitä ilmennetään läpi koko kehon. Tämän työn 
tavoitteena oli tutkia alfa-synukleiinin vaikutuksia synaptiseen signaalinvälitykseen 
erilaisissa yhteyksissä. 
α-Syn:n roolin tutkimiseksi riippuvuuden kehityksessä sen ilmentämistä verrattiin 
kahdessa rottalinjassa jotka on jalostettu vapaaehtoisen etanolin kulutuksen suhteen 
(tutkimus I). Etanolista pitävät Alko, alcohol – rotat ilmensivät enemmän α-syn:a nucleus 
accumbensin ytimessä verrattuna etanolia välttäviin Alko, non-alcohol – rottiin. 
Vakiopotentiaaliamperometria (VPA) -tulosten mukaan lisääntynyt α-syn:n ilmentäminen 
etanolista pitävissä rotissa liittyi ärsytetyn DA:n ulosvirtauksen vähenemiseen ja DA:n 
takaisinoton nopeutumiseen.  
α-Syn:n suhteen poistogeenisissä ja villityypin hiirissä tehtiin elektromyografisia 
mittauksia α-syn:n mahdollisen roolin tutkimiseksi ääreisosien kolinergisen 
signaalinvälityksen säätelyssä (tutkimus II). α-Syn:n puuttuminen aiheutti säätelyn 
puutoksia hermo-lihasliitoksen signaalinvälityksessä ja vaikeutti kehon hallinnan 
oppimista, mutta sillä ei ollut merkitystä lihasvoiman tai askelluksen kannalta.  
α-Syn:n vaikutusta yleiseen hermosolujen ärtyvyyteen ja siitä johtuvaan 
depolarisaatioon tutkittiin mittaamalla aivokuoren laajenevan vaimentuman kynnystä ja 
etenemistä α-syn:n suhteen poistogeenisissä ja villityypin hiirissä jännitemittauksella 
käyttäen tasavirtakytkettyä vahvistinta (tutkimus III). Minkäänlaisia eroja ei kuitenkaan 
havaittu hiirilinjojen välillä.  
α-Syn voi siirtyä hermosolusta toiseen soluvälitilan kautta, mutta muissa soluissa 
tuotetun α-syn:n vaikutuksia vastaanottajasolun synaptiseen signaalinvälitykseen ei 
tunneta. Niinpä α-syn:a mikroinjektoitiin villityypin ja α-syn:n suhteen poistogeenisten 
hiirten aivoihin ja vaikutukset DA-välitteiseen signaalinvälitykseen mitattiin VPA:lla. 
(tutkimus IV). Ulkosyntyisen α-syn:n havaittiin aiheuttavan muutoksia ärsytettyyn DA:n 
ulosvirtaukseen, ja vaikutukset riippuivat sisäsyntyisen α-syn:n ilmentämisestä. 
Yhteenvetona voidaan todeta, että α-syn toimii synaptisen signaalinvälityksen 
hienosäädössä. Sen pääasiallinen tehtävä on vähentää DA:n vapautusta ja nopeuttaa sen 
takaisinottoa, vaikka sillä voi olla vastakkaisia vaikutuksia kyseisiin prosesseihin tietyissä 
yhteyksissä. Käyttäytymisen tasolla α-syn:n toiminta voi vaikuttaa esimerkiksi 
mieltymykseen huumaaviin aineisiin tai kehon hallinnan oppimiseen. 
 
Luokitus: QV 126; WK 725; QV 122; WL 102.8; WL 104; WM 270 
Yleinen suomalainen asiasanasto: välittäjäaineet; dopamiini; hermosolut; hermo-lihastoiminta; 
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 1 Introduction 
Alpha-synuclein (α-syn) is a small protein, best known for its aggregation into Lewy bodies 
and other insoluble inclusions found in Parkinson’s disease (PD) which is the second most 
common neurodegenerative disease after Alzheimer’s disease (de Lau and Breteler, 2006). 
In addition, α-syn inclusions are detected in dementia with Lewy bodies (DLB), multiple 
system atrophy (MSA) and neurodegeneration with brain iron accumulation 1 (NBIA1; 
Bennett, 2005). These neurodegenerative diseases are commonly known as synucleopathies 
(or synucleinopathies in some publications). The symptoms of synucleopathies range from 
severe loss of motor control to dementia and several other cognitive symptoms. The 
physiological role of α-syn is to regulate the chemical signal transduction between neurons, 
i.e. synaptic signaling, and it is disruption of these processes which is believed to be the 
foundation of the pathology of synucleopathies (Sidhu et al., 2004). α-Syn appears to 
modulate synaptic signaling particularly in those neuronal cells releasing the 
neurotransmitter, dopamine (DA), which is responsible for motivation of our actions 
(Salamone and Correa, 2012). The goal of the current work was to elaborate some of the 
basic principles by which α-syn could affect synaptic signaling in different scenarios. 
DA release is affected by all drugs of abuse, either directly or indirectly (Hyman et al., 
2006) and there is accumulating evidence suggesting that chronic substance abuse is 
associated with differential α-syn expression. Elevated levels of the protein have been 
found in the brains of cocaine users (Mash et al., 2003) and serum of alcoholics (Bönsch et 
al., 2005a). There are also findings implying that the level of α-syn expression may 
contribute to predisposition in an individual towards addictive behavior. For example, rats 
bred for differential ethanol preference were found to have significantly increased 
expression of α-syn specifically in the hippocampus, the area of the brain responsible for 
formation of memories (Liang et al., 2003). It is crucial to understand the neurobiology of 
substance abuse and addiction because of their massive socioeconomic impacts: in Finland 
alcohol related incidents are the most frequent cause of death in the age group 15-64 years 
(14.6 % in 2006;  http://www.tilastokeskus.fi) and 9 out of 10 prisoners are addicted to some 
substance of abuse (http://www.porttivapauteen.fi). Addiction has been defined as a 
primary, chronic disease of brain reward, motivation, memory and related circuitry (The 
American Society of Addiction Medicine, http://www.asam.org). It is against this 
backround that we must learn to understand the association between α-syn and addiction. 
It has been claimed that α-syn may be the initiating factor of disease in the 
synucleopathies (Luk et al., 2012). Furthermore, it is known that the protein can be 
exocytosed from neurons and taken up into neighbouring cells (Lee et al., 2005; 2008). In the 
case of pathological forms of the protein, this translates into a spread of pathology from 
neuron to neuron (Volpicelli-Daley et al., 2011) and from one brain region to its neighbours 
(Braak et al., 2003). This has made α-syn an interesting target for new therapies (Maguire-
Zeiss, 2008). However, if pathological forms of α-syn are considered to be the enemy in the 
war against synucleopathies, the non-pathological role of the protein should first be 
understood. 
What is already known about α-syn in synaptic signaling? α-Syn has been postulated to 
regulate the synthesis, storage, release and uptake of DA (Sidhu et al., 2004) but the 
published results on the mechanisms of function and effects of the protein are rather 
diverse and often contradictory (Burré et al., 2010, Nemani et al., 2010). Therefore, the exact 
function of α-syn in dopaminergic neurotransmission still needs further study. DA and α-
syn are involved in addiction (Mash et al., 2003; Hyman et al., 2006) but the exact 
mechanisms and brain structures through which they affect the development of the 
condition still need to be elaborated. There are some histological findings pointing to 
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localization of the protein in peripheral acetylcholine-releasing neurons (Wakabayashi and 
Takahashi, 1997; Sharrad et al., 2013) but it is not clear whether α-syn has a functional role 
in peripheral cholinergic neurotransmission. α-Syn has also been shown to regulate 
glutamate (Liu et al., 2004) and noradrenaline release (Yavich et al., 2006) but it is not certain 
if this is because of α-syn’s involvement in pre-synaptic modulation of these particular 
neurotransmitter systems, or because α-syn is able to modulate the general properties of 
neuronal excitability that are common to all neurons (Adamczyk and Strosznajder, 2006; 
Hettiarachchi et al., 2009). The protein’s transfer from neuron to neuron has been shown to 
play a major part in the pathological degeneration of the dopaminergic system in 
synucleopathies (Volpicelli-Daley et al., 2011; Luk et al., 2012), but there is no evidence on 
whether the transferred, exogenous protein has any effect on pre-synaptic DA signaling.  
The current research attempted to answer these questions by applying different 
electrochemisty and electrophysiology methods in rodent models. Constant potential 
amperometry was used to measure parameters of stimulated DA overflow in rats bred for 
differential ethanol preference, and western blot was used to compare the α-syn expression 
in different parts of the striatum (study I). Comparing the phenotype of knockout mice to 
wild-type is a useful and widely used tool for elucidating the functions of individual 
proteins and thus a mouse line that has lost α-syn as a result of a spontaneous mutation 
(Specht and Schoepfer, 2001) was investigated and a gene-targeted knockout line was used 
to verify the putative findings (Abeliovich et al., 2000). The peripheral cholinergic signalling 
in the neuromuscular junction of α-syn knockout and wild-type mice was measured using 
electromyography, and the motor control of these animals was compared in different 
behavioral tests (study II). The effect of α-syn on neuronal excitability was evaluated by 
initiating and measuring cortical spreading depression (CSD) in α-syn knockout and wild-
type mice by direct current (DC) potential recording (study III). Exogenous α-syn protein 
was delivered by microinjection to the striatum of α-syn deficient and wild-type mice and 
constant potential amperometry was used to measure the effects on stimulated DA 
overflow (study IV). The aim was to evaluate the effects of new emerging treatments for 
synucleopathies which could directly decrease the levels of α-syn in the body or inactivate 
it. In particular, it was intended to increase the fundamental knowledge of the regulation of 
synaptic signaling through α-syn. 
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2 Review of the Literature 
2.1 THE SYNUCLEIN PROTEIN FAMILY, AND STRUCTURE AND 
EXPRESSION OF α-SYN 
The first section of the literature review will examine the factors that determine the 
biological activity of α-syn. First the main functions of all synucleins and possible 
redundancy between them will be reviewed. Then the structure of the protein will be 
investigated to determine which components are crucial in its synaptic localization and 
function. Finally the factors which regulate the expression of the protein will be reviewed 
as well as how their function translates into high α-syn expression in certain parts of the 
nervous system. 
2.1.1 Synucleins 
α-Syn belongs to a three-member protein family consisting of alpha-, beta- and gamma-
synuclein (reviewed by George, 2003). If one wishes to understand the function of an 
individual protein, one needs to investigate which functions and features are so central that 
they are conserved throughout the whole protein family. More importantly, knowledge of 
the overlapping expression and properties of synucleins is crucial when interpreting results 
from knockout models lacking only one or two members of the family (Chandra et al., 2004; 
Senior et al., 2008; Burre et al., 2010). It should also be remembered that some changes seen 
especially in single knockouts may be compensatory in response to the lack of the protein. 
At present only vertebrate orthologs of synucleins have been identified (George, 2003). 
The first member of the family to be found was gamma-synuclein (γ-syn), isolated from the 
cholinergic nerve terminals of of the pacific electric ray (Torpedo californica) electric organ 
(Maroteaux et al., 1988). Human (Homo sapiens) α-syn was originally identified when 
studying amyloid plaques in Alzheimer’s disease, and it was named as the non-Aβ 
component of Alzheimer’s disease amyloid precursor (NACP; Uéda et al., 1993). Later on, a 
second synuclein was extracted from human brain and named as beta-synuclein (β-syn; 
Jakes et al., 1994), even though the bovine β-syn ortholog had already been discovered 
earlier and named phosphoneuroprotein 14 kDa (PNP14; Nakajo et al., 1993). The human γ-
syn gene was found when studying risk factors for breast cancer and originally named as 
BCSG1 (breast cancer specific gene 1; Ji et al., 1997). The genes for human α-syn (SNCA), β-
syn (SNCB) and γ-syn (SNCG) are located in chromosomes 4q21.3-q22 (Chen et al., 1995), 
5q35 (Spillantini et al., 1995) and 10q23.2-q23.3 (Ninkina et al., 1998), respectively. The 
proteins encoded by these are evolutionarily conserved, and the amino-acid sequences of 
mouse (Mus musculus) and rat (Rattus norwegicus) α-syn are 95.7 % identical to human α-
syn (Gerorge, 2003; Fig. 1). Therefore one can consider that mice and rats are suitable 
models for studying the functions of synucleins. 
All synucleins are highly, but not exclusively, expressed in the brain, with β-syn being 
the most and γ-syn the least brain specific of the family (Lavedan, 1998). Within the brain, 
synucleins are expressed in the cerebral cortex, amygdala, substantia nigra (SN), striatum, 
hippocampus and thalamus (Lavedan, 1998; Ninkina et al., 1998; Ahmad et al., 2007). 
Synucleins are expressed also in other brain areas but their expression patterns are not 
identical (Li et al., 2002); the subthalamic nucleus (STN) expresses only α-syn and corpus 
callosum has α- and γ- but no β-syn (Lavedan, 1998).  
α- and β-syn tend to be localized in the pre-synaptic terminals while γ-syn appears to be 
more widely dispersed throughout the cytosol (Jakes et al., 1994; Surguchov et al., 2001). α-
Syn is present also in the nucleus, and the nuclear expression is elevated during prenatal 
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development (Zhong et al., 2010). At least human γ-syn does not appear to share the 
nuclear localization of α-syn, even though there were reports that this occurred in the 
electric ray (Maroteux et al., 1988; Specht et al., 2005). 
In the peripheral nervous system, γ-syn is the most higly expressed member of the 
family and α-syn second most higly expressed while β-syn lies below the detection limit 
(Buchman et al., 1998; Papachroni et al., 2005). All synucleins are expressed in skeletal 
muscle, and α- and γ-syn are expressed in the heart, liver, pancreas and kidney (reviewed 
by Lavedan et al., 1998). α-Syn also has also been detected in the skin, lung, kidney, spleen 
and placenta (Beyer et al., 2008) and it also has a very strong expression in erythrocytes 
(Barbour et al., 2008). The systemic expression patterns of synucleins change during 
development and aging (Buchman et al., 1998; Ninkina et al., 1998; Baltic et al., 2004) and 
especially α-syn protein levels in the brain are significantly increased in aged individuals 
(Chu and Kordower, 2007).  
The homology and similar expression patterns between α- and β-syn in the brain 
indicate that they share many functions in synaptic signaling (Chandra et al., 2004), e.g. 
both have both been shown to inhibit phospholipase D2 (PLD2) activity which is required 
for vesicle recycling in presynaptic terminals (Jenco et al., 1998; Lotharius and Brundin, 
2002). On the other hand, α- and γ-syn have been reported to bind tubulins and promote 
their polymerization (Alim et al., 2004; Zhang et al., 2011). Alpha- and beta-tubulins are 
polymerized into microtubules, the dynamic network that forms the cytoskeleton and along 
which intracellular and pre-synaptic neurotransmitter vesicles are transported.  
α- and γ-syn regulate cell cycle and survival, e.g. α-syn can inhibit apoptosis through 
regulation of p53 expression (Alves da Costa et al., 2002), and it may also exert a protective 
effect against oxidative stress (Quilty et al., 2006) and excitotoxicity (Leng and Chuang, 
2006). The main function of γ-syn appears to be promotion of proliferation through 
interactions with the poles of the mitotic spindle (Surguchov et al., 2001) and the mitotic 
checkpoint protein kinase BUB1B (Gupta et al., 2003). γ-Syn is very highly expressed in 
many types of cancer, especially in its advanced stages (Ji et al., 1997; Ahmad et al., 2007). α- 
and β-syn appear to be involved also in axonal regeneration (Quilty et al., 2002). The 
functions in cell cycle and regeneration may be another way for the synucleins to modulate 
neuronal plasticity. 
α-Syn has a tendency to aggregate into intracellular inclusions (Spillantini et al., 1997). β-
Syn has been found in the same inclusions (Galvin et al., 1999; 2000) but it may also be 
protective in synucleopathies because of its ability to prevent the aggregation and inhibit 
the spread of harmful α-syn oligomers (Hashimoto et al., 2001; Israeli and Sharon, 2009). γ-
Syn has been found in the same pathological inclusions as α- and β-syn (Galvin et al., 1999; 
2000).  
It can be concluded that redundancy between α- and β-syn is a potential problem when 
studying the pre-synaptic functions of α-syn in the brains of knockout models. γ-Syn is co-
expressed with α-syn in the peripheral nervous system, but its cellular localization and 
functions in proliferation make redundancy in pre-synaptic functions less  likely. 
2.1.2 Structure of α-syn 
If one wishes to understand the role of α-syn in synaptic signaling and in related pathology, 
it is essential to elucidate the structural properties which dictate the cellular distribution 
and function of the protein. The 14 kDa α-syn protein appears to have no stable secondary 
structure in solution, but the N-terminal domain of α-syn (residues 1-92) is folded into two 
separate alpha-helixes after binding to phospholipid membranes (Davidson et al., 1998; 
Research Collaboratory for Structural Bioinformatics Protein Data Bank, 
http://www.rcsb.org; Fig. 1). - and -syn have highly similar structures in their N-terminal 
regions (George, 2003). The helical region of α-syn consists mainly of six eleven-residue 
repeats that correspond with minor exceptions to the consensus sequence pKTKEGVaxaA,  
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Figure 1. Simplified presentation of human alpha-synuclein with known missense mutations and 
post-translational modifications. See text for exact references 
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where p represents a polar residue, a refers to an apolar residue and x is any residue 
(Davidson et al. 1998; Perrin et al., 2000). Between repeats 5 and 6, there is also a 
hydrophobic sequence of 11 residues (68-78) which does not correspond to the consensus 
sequence but still contributes to the folding of the alpha-helix. The highly hydrophobic 
NAC fragment found from amyloid plaques consists of residues 61-95 (Ueda et al., 1993). 
The C-terminal domain of synucleins is unstructured and less conserved, comprising 
mostly of acidic residues (George, 2003) but it may contribute to folding of other proteins, 
i.e. chaperone function (Ostrerova et al., 1999; Souza et al., 2000). 
Post-translational modifications can increase the size of α-syn from 14 to 19 kDa (Jakes et 
al., 1994) and they also affect the secondary structure and function of the protein. Human α-
syn is acetylated at the N-terminal methionine (M) which may be crucial to the formation of 
the alpha-helix, lipid binding properties and oligomerization of the protein (Bartels et al., 
2011; Maltsev et al., 2012; Trexler and Rhoades, 2012). Lysine (K) glycosylation, tyrosine (Y) 
nitration  and serine (S) phosphorylation are clearly associated with α-syn aggregation and 
neurodegeneration (reviewed by Beyer, 2006; see also Munch et al., 2000 and Chen et al., 
2010). S129 is the primary phosphorylation site, but there is also a secondary, non-
conserved phosphorylation site at S87, which disrupts the alpha-helical structure and 
reduces the membrane binding of the protein (Beyer, 2006; Paleologou et al., 2010). 
Ubiquitination, which usually targets proteins for degradation, is a hallmark of Lewy 
bodies and other filamentous α-syn inclusions that resist degradation (Hasegawa et al., 
2002). The ubiquitination in aggregated α-syn is concentrated around K residues 6, 10 and 
12 (Nonaka et al., 2005). There are also some modifications which are potentially 
neuroprotective. Ubiquitination of K residues 21, 24, 32 and 34 has been detected in 
monomeric α-syn in vitro and may represent a way for targeting the protein for 
degradation in vivo (Nonaka et al., 2005). Addition of small ubiquitin-like modifier 1 (SUMO 
1) to K96 and K102 (Krumova et al., 2011) and oxidation of M residues (Hokenson et al., 
2004) appear to prevent α-syn aggregation and toxicity. Phosphorylation of the C-terminal 
Y residues is potentially neuroprotective and the ratio between S and Y phosphorylation 
may be significant to the development of synucleopathies (Negro et al., 2001; Chen et al., 
2009).  
The quaternary structure of α-syn has lately been the subject for a lively debate. 
Traditionally the unstructured monomer has been considered as the main physiological 
form of the protein while oligomeric species have been considered toxic and prone to 
fibrillization (Bennett, 2005; Uversky, 2007). This view was challenged by Bartels et al. 
(2011) who stated that α-syn could exist mainly as a helically folded tetramer that resisted 
further aggregation. Species of α-syn corresponding to the molecular weight of the tetramer 
have also been reported earlier (Baltic et al., 2004). The proposal that the tetramer was the 
main physiological form of α-syn was soon disputed (Fauvet et al., 2012) but the existence 
and properties of the tetrameric form cannot be completely excluded (Maltsev et al., 2012; 
Trexler and Rhoades, 2012). 
It can be concluded that despite its relatively small size, α-syn has a complex, dynamic 
structure that allows it to perform different functions in relation to lipid membranes and as 
a soluble protein. The functionality of the protein can be affected by various post-
translational modifications. 
2.1.3 Cellular distribution of α-syn 
α-Syn is mainly expressed in the brain and particularly in the presynaptic nerve terminals 
(Iwai et al., 1995; Baltic et al., 2004). It is associated with lipid rafts on membranes (Fortin et 
al., 2004) and preferentially with small pre-synaptic vesicles (Davidson et al., 1998; Jensen et 
al., 1998). However, the association with lipid membranes is reversible (Kahle et al., 2000) 
and there appears to be an equilibrium between the membrane associated and soluble 
fractions; in the rat brain, the membrane associated portion accounts for only 15 % of the 
total amount of the protein (Lee et al., 2002) and according to an amino-acid sequence based 
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prediction, 35.4 % of human α-syn is associated with secretory vesicles while 32.2 % is 
cytosolic (Devi et al., 2008). 
In the fetus, α-syn expression is more evenly distributed also in other tissues and organs 
(Baltic et al., 2004) and data from neural progenitor cells and mice indicate that this 
expression is mostly nuclear (Schneider et al., 2007; Zhong et al., 2010). An amino-acid 
sequence based analysis has predicted that 16.2 % of human α-syn is located in the nucleus 
(Devi et al., 2008). It has been postulated that the pre-synaptic compartment is the primary 
site of α-syn expression and that increased expression drives the protein to the cell soma 
and also to the nucleus (Kahle et al., 2000; Masliah et al., 2000). In nigrostriatal neurons of 
adult mice, a toxic insult by the herbicide paraquat could increase α-syn expression, nuclear 
localization and association with histones (Goers et al., 2003). In addition, oxidative stress 
causes the protein to move to the nucleus where it binds to regulatory regions of several 
genes related to a variety of functions, including transcriptional regulation, differentiation 
of central nervous system neurons, and learning and memory (Siddiqui et al., 2012). The 
synaptic localization of the protein depends on the N-terminal region of the protein 
(residues 1-102) and the nuclear localization on the C-terminal region (residues 103-140; 
Specht et al., 2005; Burre et al., 2012). S129 phosphorylation appears to be associated with 
nuclear localization of the protein (Rieker, 2011; Amschl et al., 2013). 
The N-terminal residues 1-32 also carry a signal sequence for mitochondrial localization 
and α-syn has been found to be located in the inner membrane of mitochondria in the 
dopaminergic neurons of SN and striatum (Li et al., 2007; Devi et al., 2008). At the inner 
membrane, α-syn interacts with mitochondrial complex I of the electron transport chain.  It 
has been estimated that 16.2 % of human α-syn is associated with the mitochondria (Devi et 
al., 2008). 
2.1.4 Regulation of α-syn expression 
Differential expression of α-syn is believed to occur in addiction, PD and depression (Mash 
et al., 2003; Singleton et al., 2003; Chartier-Harlin et al., 2004; Martins-de-Souza et al., 2012). 
Therefore it is important to understand the mechanisms which regulate the level of α-syn 
expression and these are relevant also for understanding the systemic distribution of the 
protein. However, the subject has not been explicitly reviewed in the published literature. 
Neural and other growth factors up-regulate α-syn expression, which explains the high 
prenatal expression (Stefanis et al., 2001; Wang et al., 2008; Clough et al., 2011). Basic 
fibroblast growth factor (bFGF) is able to upregulate α-syn expression in the midbrain 
dopaminergic neurons but not in gamma-aminobutyric acid (GABA) releasing or cortical 
neurons (Rideout et al., 2003). This is explained by the particularly high expression of the 
specific receptor of bFGF in dopaminergic neurons (Gonzalez et al., 1995). The extracellular 
signal-regulated kinase (ERK) pathway mediates the growth factor signal from the growth 
factor receptors to transcription factors like zinc finger and SCAN domain containing 21 
(ZSCAN21) and zinc finger protein 219 (ZNF219; Clough et al., 2009). Leucine rich-repeat 
kinase 2 (LRRK2) upregulates α-syn expression through the same pathway and mutations 
in this protein are a frequent cause of autosomal-dominant PD (Carballo-Carbajal et al., 
2010). The high expression of α-syn in erythrocytes (Barbour et al., 2008) is explained by 
direct transcriptional up-regulation by GATA binding factors 1 and 2 (GATA-1 and GATA-
2), as both are essential transcription factors for blood cell development (Scherzer et al., 
2008). GATA-2 is also expressed in the frontal cortex and SN which are vulnerable to 
degeneration in synucleopathies. Nuclear receptor related 1 (NURR1) guides the 
specialization and survival of the dopaminergic system (Saucedo-Garcenas et al., 1998; 
Sakurada et al., 1999), but surprisingly, it down-regulates SNCA transcription (Yang and 
Lachtman, 2008). Mutations in the gene coding NURR1 increase the risk of PD (Le et al., 
2002). 
Some important regulatory sites in and around the SNCA sequence have been 
recognized. Poly-(ADP-ribose) polymerase-1 (PARP-1) has been shown to down-regulate 
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SNCA transcription by binding to a regulatory region known as NACP-Rep1, located 
approximately 10 kb upstream of the SNCA gene (Chiba-Falek et al., 2005). The repeat 
length in this microsatellite is known to increase α-syn expression (Fuchs et al., 2008) and 
the risk of PD and alcoholism in certain populations (Farrer et al., 2001; Mizuta et al., 2002; 
Tan et al., 2004; Bönsch et al., 2005b). Other known regulatory regions are the NURR1 and 
ZNF219 binding elements in the 5’-promoter (Cheng et al., 2008; Clough et al., 2009) and the 
GATA-1, GATA-2 and ZSCAN21 binding elements in intron 1 (Scherzer et al., 2008; Clough 
et al., 2009). Epigenetic regulation of intron 1 may have pathological significance as the level 
of methylation of its cytosine-phosphate-guanine sites (i.e. epigenetic silencing) is reduced 
in the SN, putamen and cortex of patients with sporadic PD (Jowaed et al., 2010). 
The expression of α-syn can also be post-transcriptionally regulated. SNCA’s translation 
into protein begins from exon 2 (Beyer et al., 2008). The full-length 140 residue α-syn is 
encoded by all protein coding exons (2-6), but the human protein has also three less 
expressed isoforms due to alternative splicing. The 126 residue α-syn lacks the residues 
coded by exon 3, the 112 residue α-syn exon 5 and the 98 residue α-syn exons 3 and 5 
(Beyer et al., 2004; 2006; 2008; Fig 1). The 98 and 112 residue α-syn mRNAs are upregulated 
in the brain in DLB and also by oxidative stress (Beyer et al., 2004; 2008; Kalivendi et al., 
2010) while the expression of the 126 residue α-syn appears to be reduced in DLB and 
Alzheimer’s disease (Beyer et al., 2006). Two microRNAs, mir-7 and mir-153, have been 
found to inhibit the translation into protein by binding to the 3’-untranslated region of 
SNCA mRNA (Doxakis et al., 2010). The presence of iron appears to increase the stability of 
SNCA mRNA by binding to a specific responsive element at the 5’-untranslated region 
(Friedlich et al., 2007; Febbraro et al., 2012), and iron accumulation in the brain is a typical 
feature in neurodegenerative diseases and migraine (Welch et al., 2001; Kruit et al., 2009; 
Dusek and Schneider, 2012; Mochizuki and Yasuda, 2012).  
There are environmental and life style factors which can affect α-syn expression. The 
post-transcriptional regulation of SNCA mRNA may explain why occupational exposure to 
iron increases the risk of PD (Lai et al., 2002). Exposure to pesticides and herbicides is also a 
PD risk factor (de Lau and Breteler, 2006) and the herbicide paraquat has been 
demonstrated to increase the expression of α-syn in nigrostratal neurons of mice (Manning-
Bog et al., 2002; Goers et al., 2003). Valproic acid is used for treatment of epilepsy, migraine 
and mania and this drug up-regulates α-syn expression (Leng and Chuang, 2006). Liver X 
receptor and (LXR and ) are transcription factors that use cholesterol metabolites as 
activating ligands and up-regulate SNCA transcription (Cheng et al., 2008). This suggests 
that cholesterol intake and/or its metabolism affect α-syn expression. Elevated levels of 27-
hydroxycholesterol have been found in the blood and brains of PD patients (Lee et al., 2009; 
Seet et al., 2010; Cheng et al., 2011) and a high intake of animal fat and cholesterol is known 
to increase the risk of PD (Lai et al., 2002). LXR expression is concentrated in the internal 
organs, whereas LXRis ubiqituous (Kidani and Bensinger, 2012). 
2.1.5 Systemic distribution of α-syn 
Between 0.5-1 % of the total protein in the brain is α-syn (Iwai et al., 1995). The expression is 
limited to neurons and α-syn is not endogenously expressed in astrocytes or astroglia, the 
cells that produce myelin, maintain brain homeostasis and provide support and protection 
to neurons (Ahn et al., 2012; Amschl et al., 2013). However, glial α-syn inclusions have been 
identified in synucleopathies (Tu et al., 1998; reviews by Jellinger, 2003, and Bennett, 2005). 
α-Syn expression is highest in dopaminergic and noradrenergic regions (Li et al., 2002) but 
it is also expressed in cholinergic (Dugger and Dickson, 2010) and glutamatergic neurons 
(Totterdell et al., 2010). Iwai et al. (1995) performed a comparative western blot analysis, 
according to which α-syn displayed highest protein expression in the hippocampus, 
striatum, frontal cortex and the olfactory bulb. In the same study, there was meagre 
expression at the thalamus and hypothalamus, and lowest expression in the midbrain, 
cerebellum, pontine tegmentum and medulla oblongata. Unfortunately it is not possible to 
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compare protein data from other brain areas reliably because of the methodological 
differences between studies, but the protein expression in the rat amygdala appears to be 
equal to or even more to that found in hippocampus (Jeannotte et al., 2009) whereas the 
expression in murine corpus callosum is low (Xu et al., 2011). The data on protein 
expression can be contradictory with mRNA expression because of several factors such as 
mRNA stability or the rate of protein degradation. In the case of α-syn, also the presynaptic 
localization can cause a mismatch between mRNA and protein expression in specific 
structures. This manifests itself as high protein expression in the striatum despite a low 
mRNA expression, as the protein is present mainly at the presynaptic terminals of 
dopaminergic neurons that project their axons to the area from SN and the ventral 
tegmental area (VTA) where SNCA mRNA expression is high but protein expression low 
(Mash et al., 2003; Allen Brain Atlas, human.brain-map.org).  
As mentioned, α-syn, and especially its full length version, is known to be expressed also 
in various internal organs, heart and skeletal muscle (Lavedan, 1998; Beyer et al., 2008). α-
Syn inclusions have been found within chromaffin cells of the adrenal medulla, which 
secrete adrenaline and noradrenaline into the systemic circulation (Wakabayashi and 
Takahashi, 1997). Data from mice suggest that α-syn expression in the adrenal medulla is 
concentrated in adrenaline producing cells (Khan et al., 2012). Askanas et al., (2000) reported 
that α-syn expression was concentrated to the postsynaptic side of the neuromuscular 
junction in skeletal muscle fibers and that the expression was high and diffuse across the 
cytoplasm in both regenerating and necrotic fibers. α-Syn inclusions have also been found 
in gastrointestinal mucosa of PD patients but in healthy controls α-syn in the gut is minimal 
(Forsyth et al., 2011). Even though α-syn is expressed in tyrosine hydroxylase (TH) 
expressing sympathetic nerve fibers of the heart (Marrachelli et al., 2010) the α-syn 
expressing neurons in the gastrointestinal tract are cholinergic (Sharrad et al., 2013). α-Syn 
inclusions have also been found in the cholinergic lower motor neurons (Mu et al., 2013). 
Blood and cerebrospinal fluid contain α-syn and there have been several attempts to 
establish the protein level in these sources so they could act as a biomarker for different 
synucleopathies (reviewed by Kasuga et al., 2012). Neurons of the central nervous system 
have been verified as the source of the cerebrospinal fluid’s α-syn (Mollenhauer et al., 2012); 
its level generally appears to be reduced in synucleopathies (Kasuga et al., 2012) and 
increased after traumatic brain injury (Su et al., 2010). It is easier to obtain blood samples 
than cerebrospinal fluid samples, but the results on serum and plasma α-syn as indicators 
of synucleopathies have been rather unconvincing (Kasuga et al., 2012). Since erythrocytes 
contain 99 % of the α-syn in blood (Barbour et al., 2008), whole blood samples might 
provide a better biomarker (Miller et al., 2004). 
2.2 MECHANISMS OF α-SYN FUNCTION 
The presynaptic localization and the high expression in the brain indicate that α-syn is 
important in regulating neurotransmitter release. This section of the literature review will 
summarize α-syn’s molecular mechanisms of action, and how α-syn regulates the neural 
circuitries for motor control, reward, motivation, learning and memory. It does seem that 
the effects of a-syn on synaptic signaling are a very complex and fine-tuned process, and 
are very difficult to measure and characterize. 
2.2.1. α-Syn in the control of neurotransmitter synthesis and storage 
Before a neurotransmitter can be released in a controlled manner, it must be synthesized 
and packaged into small presynaptic vesicles (Fig. 3). α-Syn may reduce the total amount of 
presynaptic vesicles by decreasing their recycling rate due to the inhibition of PLD2, as 
PLD2 synthesizes phosphatic acid which is required for recruiting the necessary proteins 
for vesicle recycling (Jenco et al., 1998; Lotharius and Brundin, 2002; Nemani et al., 2010; 
Gaugler et al., 2012).  
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PLD2 mediates also choline synthesis, and therefore inhibition of PLD2 leads to reduced 
acetylcholine levels (Zhao et al., 2001). α-Syn may also antagonize the final step in 
acetylcholine synthesis, as pathological α-syn inclusions have been found to stain positive 
for choline acetyltransferse (Dugger and Dickson, 2010) and soluble α-syn has been shown 
to co-localize with choline acetyltransferse in transgenic mice overexpressing human α-syn 
(Magen et al., 2012). The α-syn overexpressing mice also displayed a ~30 % decrease in total 
acetylcholine concentration in the cortex. Acetylcholine is an important neurotransmitter in 
the periphery, but it is unknown whether α-syn has any functional significance in 
peripheral cholinergic signaling. 
α-Syn has a more widely studied role in the control of DA synthesis. α-Syn physically 
interacts with TH which is the rate-limiting enzyme in catecholamine synthesis (Perez et al., 
2002; Fig. 2 and 3). It was also found that TH phosphorylation, which determines the 
enzyme’s activity, along with DA synthesis was reduced in response to α-syn 
overexpression (Peng et al., 2005). Serine 40 was identified as the main phosphorylation site 
determining the activation of TH and the modification was mediated by protein 
phosphatase 2A. Subsequently it was shown that silencing SNCA with siRNA could result 
in increased TH activity (Liu et al., 2008). Perez et al. (2002) did not find any changes in TH 
expression, but later studies have shown that increased expression of α-syn reduces TH 
mRNA and protein expression (Baptista et al., 2003; Yu et al., 2004; Chu and Kordower, 
2007). In addition, transgenic mice expressing a C-terminally truncated human α-syn (1-
120) have a lower striatal DA content (Tofaris et al., 2006). However, striatal DA levels in α-
syn knockout mice are unchanged (Schlüter et al., 2003; Robertson et al., 2004) or decreased 
(Abeliovich et al., 2000; Al-Wandi et al., 2010) suggesting that there are compensatory 
mechanisms occurring in the complete absence of the protein. Al-Wandi et al. (2010) 
reported that the striatal DA content was reduced in aged α-syn knockout mice when no 
compensatory mechanisms were detected, but they were not able to confirm whether the 
observed changes were because of effects on TH activity or because of α-syn’s protective 
effect on synaptic integrity. 
 
 
Figure 2. Biosynthesis of catecholamines and the main end-products of their degradation. 
Activity of TH determines not only the level of DA, but also of the other catecholamines. 
Adapted from Nestler et al., 2009 
The synthesized neurotransmitters are packaged into the presynaptic vesicles by specific 
transporter proteins, e.g. in the central nervous system catecholamines are packaged by 
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vesicular monoamine transporter 2 (VMAT2; Parsons, 2000; Fig. 3). It was reported by Guo 
et al., (2008) that VMAT2 activity was decreased in SH-SY5Y cells, in which there was stable 
overexpression of α-syn. The expressions of VMAT2 mRNA and protein were decreased in 
the α-syn transfected cells, but it remained unclear whether the decrease in activity was 
simply because of changes in expression since α-syn and VMAT2 are known to form a 
complex. The regulation of expression was verified later by siRNA silencing of SNCA 
which increased the VMAT2 expression per vesicle by 2.8-fold and total expression by two-
fold (Fountaine et al., 2008). 
2.2.2 α-Syn in the organization of synaptic vesicle pools 
Determining the exact function of α-syn in neurotransmitter release (Fig. 3) does not appear 
to be an easy task, as the literature is full of more or less contradictory reports on the 
subject. The first proof of a functional role of α-syn in neurotransmitter release came from 
Abeliovich et al. (2000). They discovered that in striatal slices of α-syn knockout mice, 
paired-pulse depression of stimulated DA release was decreased, i.e. α-syn would 
negatively regulate neurotransmitter release. DA overflow in response to repeated bursts of 
electrical stimulation suggested that α-syn could reduce the refilling rate of the readily 
releasable pool (Yavich et al., 2004). The readily releasable pool consists of vesicles that are 
located at the active zone of the terminal, in other words of vesicles that are docked to the 
pre-synaptic membrane. The results were similar with noradrenaline when its release was 
measured in knockout mice (Yavich et al., 2006). In chromaffin cells, overexpression of α-
syn reduced the number of catecholamine vesicles that were released per stimulus, 
suggesting that α-syn reduces the size of the readily releasable pool (Larsen et al., 2006). 
The regulatory effect of α-syn in neurotransmitter release is not restricted to 
catecholamines (Cabin et al., 2002; Liu et al., 2004; Gureviciene et al. 2007). Murphy et al., 
(2000) proposed that α-syn positively regulated the size of the storage pool of synaptic 
vesicles in a hippocampal cell culture; a 47 % decrease in α-syn expression by antisense 
oligonucleotide treatment reduced the amount of vesicles that were distally located from 
the pre-synaptic membrane. Nemani et al. (2010) came to an opposite conclusion; they 
showed that α-syn overexpression evoked a reduction in the size of the readily releasable 
pool which they attributed to reduced size of the recycling pool. The recycling pool consists 
of vesicles that have been reformed from the plasma membrane and are located near the 
active zone. In contrast to the earlier results (Murphy et al., 2000; Larsen et al., 2006) they 
also showed that the overexpression of α-syn in mouse neurons lowered the amount of 
vesicles at the active zone (Nemani et al., 2010). There was also a reduction in the general 
amount of vesicles at the pre-synaptic terminals. Similar changes after α-syn 
overexpression were also seen by Gaugler et al. (2012) and Yavich et al., (2005). 
Electronmicroscope images revealed that in α-syn overexpressing neurons vesicles 
appeared diffused across the axonal space instead of clustering near the presynaptic 
membrane (Nemani et al., 2010). It is possible that α-syn achieves this effect by binding the 
vesicles to microtubules (Alim et al., 2004; Wersinger and Sidhu, 2005). The general 
conclusion from all these results was that α-syn could inhibit the reclustering of vesicles 
near the active zone after exocytosis (Nemani et al., 2010). 
2.2.3 α-Syn and the SNARE-complex 
α-Syn might affect not only the vesicle pool organization, but also the actual release event 
(Fig. 3). Electronmicroscope images indicated that the amount of vesicles in the active zone 
was increased in response to α-syn overexpression in PC12 cells, a cell line originating from 
a tumor of the rat adrenal medulla (Larsen et al., 2006). Since overexpression decreased 
neurotransmitter release in the same study, it was postulated that α-syn could facilitate 
docking of vesicles but inhibit a later stage in the exocytosis process called priming. 
Priming consists of conformational changes in proteins of the soluble N-ethylmaleimide–
sensitive factor attachment protein receptor (SNARE)-complex that are required for fusion 
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of the vesicle and the presynaptic terminal membrane (reviewed by Südhof, 2012). There 
are three proteins, or sub-sets of proteins in the core of the SNARE-complex: soluble N-
ethylmaleimide–sensitive factor attachment protein 25 (SNAP-25) and syntaxin 1 at the 
terminal membrane (t-SNAREs), and synaptobrevins (1 and 2) at the vesicles (v-SNAREs). 
There are also several other proteins that guide the transient, extremely rapid folding and 
refolding of these proteins. Lundblad et al. (2012) overexpressed human α-syn in rat 
striatum, and reported that α-syn was able to inhibit a late stage of stimulated DA release 
when measured with chronoamperometry. Darios et al. (2010) performed assays in 
chromaffin and PC12 cells and determined that arachidonic acid, which is essential for the 
SNARE assembly process, was bound and isolated from the SNARE-complex by α-syn, 
resulting in a reduced amount of SNARE-complexes. They also revealed that synapses 
isolated from the brain tissue (synaptosomes) of α-syn single knockout mice displayed 
increased glutamate release. Anwar et al. (2011) did not detect any changes in the amount of 
SNARE-complexes in the striatum of α, - and -syn triple knockout mice. 
There are some results suggesting that α-syn could also facilitate SNARE-complex 
assembly. Mice with a deletion in a known SNARE-folding protein, cysteine-string protein-
α (CSPα), exhibited a decreased amount of SNARE-complexes, severe neuronal 
degeneration and reduced survival (Chandra et al., 2005). Overexpression of α-syn in CSPα 
knockout mice was able to counteract these phenotypes. Furthermore, deletion of α- and -
syn exacerbated the effects of CSPα deletion. Later on it was also shown that 
overexpression of α-syn was able to increase the amount of assembled SNARE-complexes 
in cell models (Burre et al., 2010; 2012). Mice lacking all three synucleins have a reduced 
amount of SNARE-complexes in the brain, shortened lifespan, age-dependent reduction in 
the expression of synaptobrevin 2 and a dramatic increase in the expression of CSPα (Burre 
et al., 2010). It was also shown that α-syn underwent a direct interaction with the SNARE-
proteins and it was hypothesized that α-syn had a chaperone function in folding them so 
that they were ready for priming. The functional and structural similarity between α-syn 
and the 14-3-3 proteins suggests that all synucleins might have a chaperone-like activity 
(Ostrerova et al., 1999), which has been confirmed (Souza et al., 2000). It appears that the N 
and C-terminal regions of α-syn are required for the chaperone function in SNARE-
complex assembly, while only the NAC fragment is necessary for the neurodegenerative 
effects of the protein (Burre et al., 2012). The results of Cabin et al., (2002), Liu et al. (2004) 
and Gureviciene et al. (2007) indicated that the suspected facilitation of SNARE-complex 
assembly could translate into increased hippocampal glutamate release. However, the 
evidence is indirect and it remains unclear if α-syn is able to facilitate neurotransmitter 
release and if so, under which circumstances. 
2.2.4 α-Syn in the control of neurotransmitter re-uptake 
α-Syn has a role in the control of neurotransmitter uptake, or re-uptake as the process is 
also referred to (Fig. 3, reviewed by Oaks and Sidhu, 2011). Uptake by the DA transporter 
(DAT) appears to be the main mechanism responsible for clearing the released DA from the 
extracellular space (Wightman and Zimmerman, 1990; Benoit-Marand et al., 2000; Budygin 
et al., 2002). Lee et al. (2001) were the first investigators to show a physical interaction with 
α-syn and DAT. They also showed that α-syn overexpression accelerated the maximal 
velocity of DA uptake (Vmax) in a fibroblast model. It was hypothesized that α-syn could 
bind DAT and anchor it to the extracellular membrane, as the main mechanism for 
controlling the activity of DAT is to sequester it to the cytosol, away from the cell surface 
(Melikian and Buckley, 1999). Both proteins have later been shown to be associated with 
membrane rafts (Fortin et al., 2004; Foster et al., 2008) and siRNA mediated silencing of 
SNCA in a dopaminergic neuroblastoma cell line (SH-SY5Y) resulted in a ~50 % decrease in 
DAT surface expression and a corresponding reduction in DA uptake (Fountaine et al., 
2008). The increased uptake discovered by Lee et al. (2001) evoked an increase in DA 
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induced cell death, as DA and its metabolites (Fig. 2) are capable of causing oxidative stress 
and apoptosis (reviewed by Miyazaki and Asanuma, 2008).  
The direct interaction between DAT and α-syn has not been questioned since, but it was 
shown that the facilitation of uptake may be due to the loss of cell adhesion in the 
experiment setup (Wersinger et al., 2003a). Cells that were attached to the surface of the 
container showed a significant reduction in Vmax after α-syn overexpression, but even a  
 
 
Figure 3. Proposed pre-synaptic functions of α-syn in a dopaminergic synapse. 1) α-Syn binds 
to TH and inhibits DA synthesis. 2) α-Syn inhibits the activity of VMAT2, thus attenuating the 
packaging of DA into pre-synaptic vesicles.  3) α-Syn inhibits a late stage in DA release, even 
though it has also been suggested to promote the assembly of the SNARE-complex which is 
necessary for neurotransmitter release. Release may happen in a kiss-and-run –fashion or by 
full merger of the vesicle into the extracellular membrane. 4) α-Syn has been suggested to 
promote DA re-uptake by clustering DAT to the extracellular membrane. 5) α-Syn appears to 
bind DAT also to the microtubular network, which inhibits membrane trafficking and activity of 
the transporter. 6) α-Syn inhibits PLD2 activity, which has several functions including an 
involvement in vesicle recycling. 7) α-Syn inhibits the clustering of vesicles near the active zone 
of DA release, possibly by binding them to microtubules. See text for detailed references 
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slight disruption of the adhesion by trypsination could reverse the effect of the protein and 
Vmax became increased. DA induced cell death was also reduced in non-trypsinized cells 
overexpressing α-syn. Subsequently it was shown that α-syn could prevent the membrane 
trafficking of DAT by binding it to microtubules (Wersinger and Sidhu, 2005). α-Syn 
overexpression slowed down DA uptake as earlier (Wersinger et al., 2003a), but when the 
microtubular network was disrupted pharmacologically, α-syn was again able to increase 
Vmax, and in fact it could form an even stronger complex with DAT (Wersinger and Sidhu, 
2005). It was shown that the interaction between α-syn and DAT occurred through the 
NAC fragment of α-syn, but also other parts of the α-syn transmembrane region were able 
to affect DA uptake (Wersinger et al., 2003b). 
Despite the clear changes in Vmax, which depend mainly on the surface expression of 
DAT, no statistically significant changes in the affinity of DAT towards DA (depicted by the 
Km value) have been seen in cell models in response to α-syn overexpression (Lee et al., 2001; 
Wersinger et al., 2003a; b; Wersinger and Sidhu, 2005). However, α-syn overexpression has 
caused a slight increase in the Km value consistently in all studies, suggesting that α-syn is 
able to reduce the affinity of DAT. 
The three monoamine transporters, DAT, noradrenaline transporter and serotonin 
transporter are highly homologous and show considerable redundancy (Oaks and Sidhu, 
2011). For example, in the frontal cortex of mice where DAT expression is low, DA is taken 
up through the noradrenaline transporter, even though the affinity of the other transporters 
towards DA is considerably less than that of DAT itself (Morón et al., 2002). It has been 
shown that both serotonin (Wersinger et al., 2006a) and noradrenaline transporters 
(Wersinger et al., 2006b) have a direct interaction with α-syn and that α-syn regulates their 
surface expression and thus their activity by binding them to the microtubular network. β-
Syn has not been shown to undergo a physical interaction with the monoamine 
transporters (Oaks and Sidhu, 2011), but γ-syn can have a direct interaction with the 
serotonin transporter and a negative effect on its activity, even though the effect is not as 
robust as α-syn’s (Wersinger and Sidhu, 2009). 
Even though there is clear evidence from cell models that α-syn can modulate 
monoamine uptake, functional studies performed either in brain slices (Abeliovich et al., 
2000; Senior et al., 2008; Anwar et al., 2011) or whole brains (Yavich et al., 2004; 2006) of 
single, double or triple knockout animals have not been able to confirm this proposal. It 
was also reported that DAT expression is unchanged in α-syn knockout mice (Schlüter et 
al., 2003). However, it was later shown by Bellucci et al. (2011) that mice with a spontaneous 
deletion of α-syn have a 34-44 % reduction of total DAT expression in the striatum. 
Furthermore, the transgenic mice expressing truncated human α-syn displayed a 59-95 % 
increase in DAT expression in comparison to wild-type mice. Lundblad et al. (2012) showed 
that overexpression α-syn exerted a functional effect on DA re-uptake in a physiological 
environment, but the results were contradictory to the reported effects on DAT expression 
by Bellucci et al, (2011), as rats with a virally induced overexpression of human α-syn in 
their nigrostriatal neurons showed significant reduction of the DA re-uptake rate in the 
striatum after K+-induced release (Lundblad et al., 2012). The reduction of the rate was ~50 
% ten days after vector injection and ~80-90 % at the subsequent time points (3-16 weeks). It 
was shown that the dramatic decrease in re-uptake was not only because of changes in 
DAT activity but also because of axonal degeneration. The evidence described above shows 
that α-syn is able to affect DA re-uptake, but it remains unclear which of the two proposed 
mechanisms of function (Lee et al., 2001; Wersinger and Sidhu, 2005; Fig. 3) is the primary 
one, and if the control of re-uptake is part of the pathological properties of α-syn or the 
normal regulation of synaptic signaling. 
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2.2.5 Control of striatal dopamine release by other neurotransmitter systems 
There is a complex circuitry within the basal ganglia which controls the activity of the 
dopaminergic neurons. The connectivity of the striatum is important for understanding its 
function, and for clarifying the role of α-syn in broader concepts.  
Almost all, 90-95 %, of striatal post-synaptic neurons are GABA releasing medium spiny 
neurons (MSNs; Kawaguchi, 1993; Bolam et al., 2000; Nestler et al., 2009; Wichmann and 
DeLong, 2010). Type 1 MSNs express the D1 DA receptor and release substance P and 
dynorphin as co-transmitters. They have direct projections to the SN, and because 
activation of D1 receptors is stimulatory (Gs-coupled), their activation leads to release of 
GABA in the SN, which in turn is inhibitory. Thus, type 1 MSNs form a negative feedback 
loop known as the direct pathway. Type 2 MSNs express the D2 DA receptor and release 
enkephalin as a co-transmitter. Type 2 MSNs have projections to globus pallidus externa 
which has inhibitory projections to the SN and globus pallidus interna. Since the activation 
of D2 receptors is inhibitory (Gi/o coupled), binding of DA to D2 receptors of type 2 MSNs 
leads to disinhibition of inhibitory input to the SN, i.e. inhibition of DA release in the 
striatum. This is known as the indirect pathway. Globus pallidus externa has a regulatory 
loop to nigral DA neurons also through the STN which provides an excitatory 
(glutamatergic) input to the SN.  
Dopaminergic projections in the striatum possess pre-synaptic nicotinic receptors 
(Champtiaux et al., 2003) but only 1-2% of striatal neurons are tonically active non-spiny 
cholinergic interneurons (Kawaguchi, 1993) and dopaminergic neurons synapse with some 
of them (Chang, 1988). Despite their low number, cholinergic interneurons exert important 
modulatory actions on DA release (reviewed by Threlfell and Cragg, 2011). It appears that 
cholinergic activation is required for the dopaminergic neurons to modify their release 
according to the inputs which they are receiving (Rice and Cragg, 2004). The cholinergic 
modulation of striatal DA release through the nicotinic receptors may be linked to the 
postulated protective role of smoking against PD (Lai et al., 2002; de Lau and Breteler, 2006). 
2.2.6 Significance of α-syn to motor functions  
Motor symptoms are frequent in synucleopathies and PD is often defined as a motor 
syndrome (McKeith et al., 2004; Nestler et al., 2009; Ubhi et al., 2011; Fritsch et al., 2012; 
Dusek and Schneider, 2012). The motor symptoms in PD begin asymmetrically but start to 
affect both sides of the body as the disease progresses, and include resting tremor, 
bradykinesia, Parkinsonian gate, postural instability and micrographia. Motor symptoms in 
the face and neck include facial impassivity, dysphagia and difficulties in producing speech 
(Logemann et al., 1978; Hartelius and Svensson, 1994; Johnston et al., 1995). 
Human motor functions are controlled by two main systems, the pyramidal and 
extrapyramidal systems (reviews by Bolam et al., 2000 and Obeso et al., 2008). The 
pyramidal system, or corticospinal tract as it is also called, consists of upper and lower 
motor neurons. The glutamatergic upper motor neurons project from the motor cortex to 
lower motor neuron somas in the anterior horn of the spinal cord. The cholinergic lower 
motor neurons innervate the striated skeletal muscles. The striated muscles of the face and 
neck are controlled by the corticobulbar system that has its lower motor neuron somas in 
the brain stem. Degeneration and α-syn inclusions can be detected in the lower bulbar 
motor neurons in PD (Mu et al., 2013). The cholinergic lower motor neurons activate 
skeletal muscles through a specialized synaptic structure known as the neuromuscular 
junction. The functionality of the neuromuscular junction can be evaluated using repetitive 
stimulation of motor axons and measuring the amplitudes of the resulting compound 
muscle action potentials (CMAPs) with electromyography (AAEM Quality Assurance 
Committee, 2001; Boërio et al., 2009). This methodology is widely used for diagnosing 
diseases of the neuromuscular junction, such as myasthenia gravis and Lambert-Eaton 
myasthenic syndrome.  
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The extrapyramidal system consists mainly of the basal ganglia, cerebellum and several 
brain stem nuclei (Bolam et al., 2000 and Obeso et al., 2008). The basal ganglia and thalamus 
are in a feedback loop with the motor and other parts of the cerebral cortex, which enables 
generation and initiation of voluntary movement. Within the basal ganglia, the DS and 
globus pallidus have connections with each other and the STN, SN and mediodorsal 
nucleus of the thalamus. The death of dopaminergic cells in the SN pars compacta leads to 
the cardinal motor symptoms in PD (Fritsch et al., 2012). 
Since α-syn can be found throughout the pyramidal and extrapyramidal systems (Iwai et 
al., 1995; Beyer et al., 2008; Mu et al., 2013) and motor symptoms are prevalent in 
synucleopathies, it would seem plausible that α-syn serves some function in the control of 
movement. This kind of function might be revealed by performing basic behavioral tests for 
motor control in α-syn knockout models. However, the first published results investigating 
this topic detected no differences between wild-type and α-syn knockout mice in motor 
performance (Cabin et al., 2002). Clear motor impairments were not detected in knockout 
mice in later studies (Yavich et al., 2005; Senior et al., 2008), even though reduced movement 
velocity was recorded in α-syn knockout mice freely exploring in an open field test 
(Kokhan et al., 2012). When the topic was studied in transgenic mice expressing mutated, 
truncated and wild-type human α-syn, it was found that they developed age-dependent 
motor impairments (van der Putten et al., 2000; Yavich et al., 2005; Tofaris et al., 2006; 
Amschl et al., 2013). Interestingly, these impairments may be related to an age-dependent 
increase of human α-syn protein levels alone, while the total α-syn expression is unchanged 
(Amschl et al., 2013). Mice overexpressing their own version of the protein did develop 
motor impairments after 7 months of age, as measured by Rotarod test, but the α-syn 
protein level in these mice was as much as six fold higher in comparison to wild-type 
(Rieker et al., 2011). Their initial motor performance at two months of age was also worse 
than their controls, but after a few training sessions they were able to improve it to the level 
of their wild-type counterparts, suggesting that they might have problems in learning 
motor skills. Nonetheless, it is not clear if these changes are attributable to the 
neurodegenerative effect of α-syn, or if α-syn has a functional role in the control of 
movement. The observation that α-syn knockout mice have no phenotype related to motor 
function may be due to redundancy and the mildness of the phenotype. 
2.2.7 Dopamine and motivation 
α-Syn modifies the function of dopaminergic synapses in the striatum (Abeliovich et al., 
2000; Yavich et al., 2004), and thus if one wishes to understand the putative impact of α-syn 
on behavior and its pathology, it is essential to examine the behavioral significance of 
striatal DA signaling.  Striatal DA is known to motivate actions and activities by reinforcing 
positive action outcomes (revieved by Salamone and Correa, 2012) and also α-syn has been 
shown to modulate reward processes (Oksman et al., 2006). However, experiments with 
crab-eating macaques (Macaca Fascicularis) indicated that DA does more than simply encode 
reward (Ljungberg et al., 1992; Schultz et al., 1993; Hollerman and Schultz, 1998). Most of the 
DA neurons of the SN pars compacta and VTA were activated by reward primarily during 
the early stages of the learning process when it was not yet known which action would 
yield a reward. The number of activated neurons lessened gradually as the action-reward 
relationship became clear to the macaques, and only ~1/3 of the DA neurons were activated 
consistently with each presentation of the reward. Furthermore, the activity of the DA 
neurons was reduced when the animals knew to expect reward but it was subsequently 
denied. The conclusion was that DA codes for reward prediction error (Hollerman and 
Schultz, 1998). 
When the matter was studied in the ventral striatum of rodents (Fig. 4), it was noted that 
the extracellular DA level increased in response to unexpected reward in nucleus 
accumbens shell (AcbSh), suggesting that the neurons activated primarily by novel reward 
projected to this region (Corbit et al., 2001; Bassareo et al., 2002). In addition, an aversive 
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stimulus (taste of quinine) and stimulus signifying potential danger (smell of red fox urine) 
caused DA level to be elevated in AcbSh when presented to the animal for the first time, 
suggesting that the DA release in this region codes novelty. DA level in nucleus accumbens 
core (AcbC) increases also in response to a previously known reward. When the known 
reward is associated with a preceeding cue, the cue alone is sufficient to trigger DA release 
in the neurons projecting to AcbC (Schultz, 1986; Ljungberg et al., 1992; Cacciapaglia et al., 
2011). DA release in AcbC appears to be necessary for initiation (motivation) of actions 
which require relatively high effort (Cousins and Salamone, 1994; Salamone et al., 2007; Yin 
et al., 2008; reviewed by Salamone and Correa, 2012).  
The dorsal striatum (DS) also controls motivation of different activities. In rodents, DS 
has been traditionally referred to as the caudate putamen (CPu; Fig. 4) and it corresponds 
to two clearly separate structures in primates: caudate nucleus and putamen (Joel and 
Weiner, 2000; Grahn et al., 2008). The functions and connectivity of the rodent medial DS 
correlate roughly with those of the putamen while lateral DS corresponds to the caudate 
nucleus. Lateral DS (or caudate nucleus) appears to be important to initial acquisition of 
motor functions and habit formation (Pisa and Cyr, 1990; Yin et al., 2004), while medial DS 
(or putamen) is essential for reversal learning and adapting to new situations by switching 
strategies (Pisa and Cyr, 1990; Ragozzino et al., 2002). Medial DS may have some 
significance also in spatial learning (Devan and White, 1999). 
 
 
Figure 4. Schematic presentation of dopaminergic pathways ascending from the sunstantia 
nigra pars compacta and ventral tegmental area and their main projection areas in rodent brain. 
Adapted from Honkanen (1999) and Hyman et al. (2006) 
2.2.8 α-Syn, learning and long-term memory 
Learning means acquiring new or modifying old memories, behavioral patterns, skills, 
values or preferences. It requires neurons to modify the activity of their synapses, i.e. 
synaptic plasticity (reviewed by Cooke and Bliss, 2006). It is believed that α-syn modifies 
the signaling of dopaminergic synapses in the striatum (Abeliovich et al., 2000; Yavich et al., 
2004) and the experiments on reward prediction error have suggested that striatal DA 
release has important functions in learning processes (see section 2.2.7). PD is a 
synucleopathy defined by the loss of dopaminergic connections to the striatum, and in 
addition to dementia its cognitive symptoms include difficulties in some functions essential 
to learning, such as set-switching, problem solving, concept formation, decision making, 
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working memory and attention (Nestler et al., 2009; Fritsch et al., 2012; Svenningsson et al., 
2012). Attentional deficits have been described also in another synucleopathy, NBIA1, 
which is associated with attention deficit hyperactivity disorder (ADHD; Assami et al., 
2011). If one takes all these conciderations into account, then it seems likely that α-syn 
function and related pathologies are connected to learning and memory. 
The effects of α-syn on learning have been studied in humans. The duplication of the 
SNCA locus can be a great tragedy to its carriers (Chartier-Harlin et al., 2004) but it does 
provide a unique opportunity to study the significance of α-syn in cognitive functions (Keri 
et al., 2010). The duplication inhibited reward-oriented learning in a simple two-choice task. 
This concurs with the results from mice which indicated that in the absence of α-syn 
reward-motivated behavior was increased (Oksman et al., 2006). However, it was also 
shown that in α-syn knockout mice punishment-oriented learning was impaired in passive 
and active avoidance tests (Kokhan et al., 2012). 
The first evidence that α-syn would be able to affect learning and long-term memory in a 
non-pathological manner came from the zebra finch (Taeniopygia guttata), as mRNA of the 
α-syn zebra finch homolog synelfin was differentially expressed in brain areas crucial to 
song learning depending on the phase of the learning process (George et al., 1995). The 
formation of long-term memory depends on a type of synaptic plasticity known as long-
term potentiation (LTP) and of its inverted equivalent, long-term depression (LTD; Bliss 
and Collingridge, 1993; Cooke and Bliss 2006). In LTP, the synaptic signaling between two 
neurons is enhanced when both neurons are stimulated synchronously (Bliss and Lomo, 
1973; Gustafsson et al., 1987). LTP in the hippocampus is essential for the formation of long-
term spatial memory (Morris et al., 1986). Because α-syn has high expression (Iwai et al., 
1995) and functional significance (Abeliovich et al., 2000; Cabin et al., 2002; Nemani et al., 
2010) in the hippocampus and medial DS, it would seem plausible that the protein has 
some effect on spatial learning and memory. α-Syn is also able to facilitate hippocampal 
LTP (Liu et al., 2004; Gureviciene et al., 2007).  
Initial results from Morris water maze tests revealed no difference in spatial learning 
between α-syn null and wild-type mice when they were 6 months old (Chen et al., 2002). 
When spatial learning was measured in a similar test in 10 month old mice of different 
lineage, α-syn knockouts displayed impaired performance (Kokhan et al., 2012). The 
impairment of spatial learning was very mild, and the same was detected in double 
knockout mice lacking α- and γ-syn (Senior et al., 2008). Subsequently, it was recently 
reported that improved spatial memory in rats, measured by t-maze test, was associated 
with a ~1.5-fold increase in hippocampal α-syn expression after perilla (Perilla frutescens) 
diet (Lee et al., 2012). Perilla seeds and oil are very high in α-linoleic and omega-3 fatty 
acids which are essential for neural development (reviewed by Karr et al., 2011). However, 
dementia and learning deficits are prevalent in synucleopathies (McKeith et al., 2004; 
Svenningsson et al., 2012) and several mouse models that overexpress α-syn develop 
pathological α-syn inclusions, and display impaired LTP and memory function (Lim et al., 
2011; Costa et al., 2012; Magen et al., 2012). Overall, it appears that α-syn has a function in 
promoting learning and memory, but the effect is mild, difficult to detect in knockout 
models and easily masked by the neurodegenerative effects of α-syn overexpression. 
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2.3 α-SYN IN DISEASE 
This section of the literature review will examine the evidence that links altered α-syn 
expression to substance abuse and addiction but it will also review α-syn’s aggregation and 
how α-syn and its inclusions spread across the brain in PD. The mechanisms by which α-
syn triggers neurodegeneration in synucleopathies will be reviewed as well as how these 
mechanisms relate to the non-pathological function of α-syn in synaptic signaling. 
2.3.1 α-Syn in substance abuse and addiction 
Drugs of abuse are both rewarding and reinforcing, and they target the ascending 
dopaminergic pathways from the VTA, either directly or indirectly (for review, see Koob 
and Moal, 2001 and Hyman et al., 2006). The reward system of the brain has evolved to 
motivate individuals to seek natural reinforcers, such as food, water and sex, but drugs of 
abuse can easily take over the system. It can be said that substance abuse harnesses and 
overdrives the neural circuits meant for reward-oriented learning, which ultimately leads 
to addiction.  
The first evidence that α-syn might be involved in the neurobiology of substance abuse 
and addiction came from post mortem samples of cocaine abusers, which displayed elevated 
α-syn mRNA and protein expression in the SN and VTA (Mash et al., 2003). Qin et al. (2005) 
found that the expressions of α-syn and DAT were elevated in the DS of cocaine abusers. 
Brenz Verca et al. (2005) reported that in rats repeated doses of cocaine over a period of six 
hours (4 × 30 mg/kg i.p.) were sufficient to elevate Snca mRNA in the hippocampus, DS and 
tegmentum when measured 24 h later. Viral overexpression of α-syn in the nucleus 
accumbens of rats induced an increase in cocaine self-administration and cocaine induced 
locomotor activity (Boyer and Dreyer, 2007). Accumbal α-syn protein expression might be 
linked to drug craving, since it was found to be increased in rats which did not stop their 
drug seeking behaviour after conditioned cocaine treatment, in comparison to rats that did 
stop (del Castillo et al., 2009). Drug craving also correlated with serum levels of α-syn in 
recently abstinent cocaine users, and the serum levels were significantly higher in 
comparison to control subjects (Mash et al., 2008). Kobayashi et al., (2004) reported that 
polymorphisms in intron 1 of SNCA were associated with metamphetamine dependence in 
Japanese female population. These results suggest that differential expression of α-syn in 
the reward system of the brain may be both a cause and a consequence of drug abuse. 
Cocaine and metamphetamine act mainly by increasing synaptic DA levels, cocaine by 
blocking the function of DAT, and metamphetamine by reversing the function of VMAT2, 
which leads to an increase in intracellular DA and reversal of DAT function (Budygin et al., 
2002; Hyman et al., 2006). However, even the abuse of substances which do not affect the 
dopaminergic system directly, such as opiates, appears to have an association with α-syn. 
Opiate use (or abstinence from opiates) was reported to have long-term affects on α-syn 
expression in rat brain (Ziolkowska et al., 2005). Ethanol is known to affect the 
dopaminergic system indirectly by facilitating GABAA receptor function and inhibiting N-
methyl-D-aspartic acid (NMDA) glutamate receptor function, even though ethanol’s exact 
mechanisms of function are not fully understood (Nestler et al., 2009). α-Syn protein levels 
have been found to be higher in the serum of alcoholics in comparison to controls, and the 
protein level was positively correlated with alcohol craving among the addicts (Bönsch et al., 
2005a). Foroud et al. (2007) reported that 8 single nucleotide polymorphisms in the SNCA 
locus were associated with alcohol craving, but not with addiction. Addiction was instead 
found to be associated with repeat length in the SNCA regulatory region NACP-Rep1, 
suggesting that differential expression of the protein might be a confounding factor also in 
alcohol dependence (Bönsch et al., 2005b; Fuchs et al., 2008). Changes of α-syn expression 
linked with alcohol abuse do not appear to contribute to α-syn aggregation, as the amount 
of α-syn inclusions was not found to be different between heavy consumers and control 
subjects in a post mortem histopathological study (Aho et al., 2009). 
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Genetic vulnerability factors to substance abuse have been studied using various animal 
models, including pairs of rodent lines that have been bred based on their preference for 
ethanol (reviewed by Green and Grahame, 2007). In one such pair (P/nP rats), high Snca 
mRNA expression was detected in the alcohol preferring (P) line (Liang et al., 2003). The 
increased expression was linked to a mutation in the 3’-untranslated region of Snca mRNA 
which is believed to increase the stability of the mRNA. The high mRNA expression 
translated into significantly elevated (1.7-fold) α-syn protein expression selectively in the 
hippocampus. There was a trend towards increased protein expression (1.6-fold) also in the 
CPu of the alcohol preferring rats. However, it was recently reported that mice with a 
spontaneous deletion of α-syn show dramatically increased preference for 10 % ethanol 
when compared to α-syn expressing controls (López-Jiménez et al., 2013). The authors 
attributed this to compensatory mechanisms or downstream effects of the deletion, such as 
an increase in cannabinoid receptor 1 (CB1) expression in the hippocampus (~3-fold) and 
amygdala (~8-fold). The expression levels of these receptors remained unchanged in the 
striatum and cortex. 
Another pair of rat lines bred for differential ethanol preference is readily available in 
Finland; the Alko, non-alcohol (ANA) and Alko, alcohol (AA) rats. Their breeding program 
was started in the Alko Research Laboratories (Helsinki, Finland) by Dr. Kalervo Eriksson 
in the 1960’s (Eriksson, 1968; reviewed by Sommer et al., 2006). Nowadays the lines are 
maintained by the National Institute for Health and Welfare (Helsinki, Finland). Their 
neurochemistry has been widely studied, and the striatal DA content has been postulated 
to be higher in the ethanol preferring AA rats in comparison to non-preferring ANA rats 
(Ahtee and Eriksson, 1975; Kiianmaa et al., 1991). However, in vivo microdialysis in the 
nucleus accumbens of the two lines showed identical extracellular DA levels and elevations 
in DA levels after an ethanol challenge (Kiianmaa et al., 1995). The maximal amount of D2 
DA receptors is lower in the brain of AA rats (Kiianmaa et al., 1991) but there are no 
significant differences between the rat lines in the affinity of D1 and D2 DA receptors 
(Syvälahti et al., 1994). The rapid dynamics of DA release and re-uptake or α-syn expression 
have not been studied in this particular model in the past. 
It is clear that changes in α-syn expression are associated with the development of 
addiction. However, the association of α-syn with genetic background of addiction is 
uncertain, and data on the exact neurotransmitter systems and brain structures linking α-
syn to addiction are inconsistent. 
2.3.2 α-Syn in other psychiatric disorders 
There is some evidence that depression is linked with α-syn associated disorders. 
Alcoholism doubles the risk of depression and vice versa (Boden and Fergusson, 2011), and 
56 % of PD patients can be diagnosed with depression (Yamanishi et al., 2013). Depression 
is frequent also in other synucleopathies (reviews by McKeith et al., 2004; Ubhi et al., 2011 
and Dusek and Schneider, 2012). In some PD cases, depression preceeds the onset of other 
symptoms (Fukunishi et al., 1991; Merschdorf et al., 2003) and a previous history of 
depression more than doubles the risk of PD (Leentjens et al., 2003). Furthermore, non-
synucleopathy related Lewy body pathology may increase the risk of depression (Lopez et 
al., 2006; Iritani et al., 2008). Beck depression inventory scores correlate with serum α-syn 
mRNA levels in females with eating disorders (Frieling et al., 2008) and with NACP-Rep1 
repeat length in reportedly healthy individuals (Lenz et al., 2011). Martins-de-Souza et al., 
(2012) reported that α-syn protein expression was 1.5 fold in dorsolateral prefrontal cortex 
of patients with major depression in comparison to healthy controls. The monoamine 
theory states that depression is caused by disrupted DA, noradrenaline and especially 
serotonin signaling, and most of the current pharmacological treatments are designed to 
increase the tone of these neurotransmitters within the synapse (reviewed by Nutt, 2008). 
However, more modern theories suggest that loss of synaptic plasticity lies at the core of 
the disease and that it can be fought by promoting growth factor function (for review, see 
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Thakker-Varia and Alder, 2009). Considering the role of α-syn in synaptic signaling and 
plasticity, its implication in depression is not surprising. 
α-Syn appears to have little involvement with other psychiatric disorders. Lewy body 
pathology has been suggested to be less frequent in schizophrenia patients (Jellinger, 2009) 
but there do not seem to be significant changes occurring in total α-syn expression during 
the course of the disease (Scarr et al., 2006; Pennington et al., 2008; Gray et al., 2010; Noori-
Daloii et al., 2010). 
2.3.3 α-Syn aggregation in synucleopathies 
Synucleopathies are a group of neurodegenerative disorders which share similar 
intracellular proteinaceous lesions with aggregated, insoluble α-syn (Spillantini et al., 1998; 
Jellinger, 2003). The inclusions contain also other proteins and they can be found in 
perikarya and axonal processes of practically all neuron types of the brain, and they are 
also present in glia. α-Syn inclusions have also been found in peripheral neurons 
(Wakabayashi and Takahashi, 1997; Orimo et al., 2007; Mu et al., 2013). At least five different 
α-syn inclusions defined by morphology and localization have been identified: Lewy 
bodies, Lewy neurites (also known as dystrophic neurites), glial cytoplasmic inclusions, 
neuronal cytoplasmic inclusions and axonal spheroids (Spillantini et al., 1997; Arima et al., 
1998; Tu et al., 1998; Braak et al., 1999; Galvin et al., 2000). Lewy bodies can be further 
divided into classical (or brain stem) and cortical Lewy bodies (Jellinger, 2003).  
Monomeric α-syn oligomerizes when it folds into a beta-sheet like structure (El-Agnaf et 
al., 1998). Small oligomers then aggregate into larger protofibrils and later into fibrils which 
form the large inclusions detected in synucleopathies. Iron, calcium and some other metals 
are able to promote α-syn aggregation (Uversky et al., 2001; Lowe et al., 2004; Kostka et al., 
2008). Three missense mutations of SNCA causing rare forms of familial PD also facilitate 
the oligomerization of the protein (Fig. 1). The first mutation leads to a substitution of 
alanine with threonine at residue 53 (A53T; Polymeropoupolos et al., 1997), the second in an 
alanine to proline change at residue 30 (A30P; Kruger et al., 1998) and the third to a 
glutamate being replaced lysine at residue 46 (E46K; Zarranz et al., 2004). All three 
mutations promote α-syn oligomerization, but only the A53T and E46K mutations appear 
to increase its fibrillization (Conway et al., 1998; 2000; Greenbaum et al., 2005). The 
mutations lead to disruption of the secondary structure, revealing the hydrophobic 
residues within the alpha-helixes (Bussell and Eliezer, 2001; Eliezer et al., 2001; Bodner et al., 
2010).  This conformational change promotes the assembly of α-syn into intermolecular 
beta-sheets and thus facilitates the protein’s aggregation. 
Even though Lewy bodies and other large α-syn inclusions are the defining 
characteristics of synucleopathies, they do not appear to be the toxic species and may be 
even neuroprotective (Tompkins and Hill, 1997; Rideout et al., 2001; Tanaka et al., 2004). It is 
believed that the smaller oligomeric and protofibrillar species are the actively harmful form 
of the protein, and aggregation into larger bodies might be one way to neutralize these 
species (Bennett, 2005; Uversky, 2007). The α-syn protofibrils have been shown to form 
pore-complexes which affect membrane permeability (Volles et al., 2001; Lashuel et al., 2002; 
Lowe et al., 2004; Kostka et al., 2008). In conjunction with the other obvious defects in 
cellular integrity, this may cause leakage of vesicular DA into the cytosol where it can cause 
oxidative stress and cell death (Miyazaki and Asanuma, 2008).  
Disruption of the native pre-synaptic functions of the protein by misfolding and 
oligomerization may well contribute to the pathology, since it was discovered that in DLB, 
90 % of α-syn is concentrated in small aggregates outside Lewy bodies in the pre-synaptic 
terminals (Kramer and Schulz-Schaeffer, 2007). Recently it was reported that large α-syn 
oligomers inhibit neurotransmitter exocytosis in PC12 cells by binding to synaptobrevin 2 
and thus prevent the formation of the SNARE-complex (Choi et al., 2013). It remains unclear 
how much of the neurodegeneration in synucleopathies is due to loss of native α-syn 
function, and to what extent there is gain of toxic function through oligomerization. 
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2.3.4 α-syn and neuronal excitability 
An interesting aspect in the pathology related to oligomeric forms of α-syn is the potential 
effect on postsynaptic excitability.   Diogenes et al. (2012) and Martin et al., (2012) reported 
that α-syn oligomers (but not monomers or fibrils) were able to facilitate calcium influx in 
hippocampal slices and cell cultures. This was postulated to happen through activation of 
glutamate activated calcium channels, but it remains unclear if the pore-structures 
comprised of oligomeric α-syn are able to contribute to this effect (Volles et al., 2001; 
Lashuel et al., 2002; Kostka et al., 2008). Since calcium is able to facilitate the formation of α-
syn oligomers (Lowe et al., 2004) abrupt strong increases in intracellular calcium levels may 
initiate a vicious cycle of α-syn aggregation and neurodegeneration. A constantly activated 
calcium influx was shown to disrupt normal LTP, which might explain the deterioration of 
learning and memory in synucleopathies.  
There are also results suggesting that facilitation of calcium influx is a part of the normal, 
non-pathological function of α-syn. In experiments reported by Adamczyk and 
Strosznajder (2006), α-syn and especially its NAC-fragment were able to facilitate calcium 
influx, whereas β-syn had no significant effect. Pharmacological evidence and the rapid 
mechanism of action suggested that α-syn could potentiate the function of N-type voltage-
gated calcium channels. The results of Hettiarachi et al. (2009) suggested that the facilitation 
by α-syn occurred primarily through up-regulation of L-type voltage-gated calcium 
channels. The effect on calcium influx was reduced by pathological mutations of α-syn. 
However, it remains unclear whether the postulated facilitation of calcium influx can 
translate into modulation of neuronal excitability in vivo. As mentioned earlier (section 
2.2.3), there is indirect evidence suggesting that α-syn could facilitate neurotransmitter 
release. This evidence is largely based on the measurement of post-synaptic potentials, and 
therefore it is essential to determine whether the measured effects depend on pre-synaptic 
mechanisms of neurotransmitter release or on changes in neuronal excitability. 
Neuronal excitability can be evaluated in vivo by measuring the properties of an 
electrophysiological phenomenom known as cortical spreading depression (CSD) with DC 
potential recording (reviewed by Charles and Brennan, 2009; Dreier, 2011 and Eikermann-
Haerter et al., 2012). CSD is a slowly propagating wave of hyperexcitability followed by 
total neuronal depolarization. It can be inhibited by glutamate antagonists and calcium 
channel blockers. It is considered as the electrophysiological manifestation of migraine 
aura, and it can also be triggered in traumatic brain injury, hypoxic conditions and 
epilepsy. The primary parameters of excitability in stimulus evoked CSD are threshold of 
initiation and speed of progression, but also other properties of the depolarization wave 
can be measured.  
2.3.5 α-Syn degradation 
Disruption of α-syn elimination is a potential cause of synucleopathies, and differences in 
degradation processes may explain differences in α-syn protein expression levels. 
Misfolded, otherwise damaged or excess proteins are typically targeted to proteasomal 
degradation by ubiquitination, but in synucleopathies, the activity of the proteasome 
protein complex might be inhibited (McNaught and Jenner, 2001; Rideout et al., 2001). 
Mutations in two genes coding proteins of the ubiquitine-proteasome system (UCHL1, 
PARK2) have been found to be causes of familial PD (Nestler et al., 2009). α-Syn can be 
degraded also through autophagocytosis, a process where damaged proteins or organelles 
are packaged within lipid vesicles, and merged with lysomomes which contain acidic 
hydrolases that break down the content of the vesicle (Webb et al., 2003). A loss of function 
–mutation in a gene coding the lysosomal protein probable cation-transporting ATPase 
13A2 has been identified as a cause of familial PD (Ramirez et al., 2006). Cytosolic α-syn can 
be taken up directly into lysosomes, but the A30P and A53T mutations appear to inhibit 
this process (Cuervo et al., 2004). If ubiquitination is inhibited, α-syn starts to be eliminated 
mainly by autophagocytosis (Rott et al., 2012). However, autophagosomes may not be as 
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efficient in α-syn degradation as proteasomes, and having to resort to autophagocytosis can 
lead to accumulation of α-syn. 
2.3.6 Spread of α-syn inclusions in synucleopathies 
Lewy bodies and neurites spread across the brain over the course of PD and this 
phenomenom has been described by a scale known as Braak-staging (Braak et al., 2003). In 
the non-symptomatic stage, the first inclusions appear to the medulla oblongata, pontine 
tegmentum and the olfactory bulb. The symptoms begin to appear when inclusions spread 
to SN, areas of the midbrain and basal forebrain and the cortical regions are those last to be 
affected. There is little variation in the order of the spread between individuals with 
sporadic PD. A similar orderly spread is seen with amyloid-beta pathology in AD, even 
though the order of affected regions is different (Braak and Braak, 1991).  
In 2005 it was shown by Lee et al. that monomeric and oligomeric α-syn could be 
exocytosed from SH-SY5Y cells. It was also claimed that the α-syn in secretory vesicles was 
more prone to aggregate than the cytosolic protein. Subsequently, these workers reported 
that the exocytosed protein could be taken up by other cells (Lee et al., 2008). This fueled the 
idea that the reason for Braak-staging was seeding of α-syn from one cell to the next, 
although a theory of seeding in neurodegenerative diseases had been proposed even earlier 
(Lansbury, 1997). According to the pathological protein transfer theory, misfolded, 
aggregation prone α-syn is secreted and taken up into a recipient cell, where it is able to 
propagate the misfolding and aggregation of the recipient cells own α-syn, much like the 
prion protein in the transmissible spongiform encephalopathies (Luk et al., 2012; Angot et 
al., 2012). Convincing proof for the theory was provided by the observation that α-syn 
inclusions spread also to neurons which had been grafted to SN of PD patients (Kordower 
et al., 2008; Li et al., 2008). Volpicelli-Daley et al. (2011) stated that exposure of axonal 
terminals to pre-formed α-syn fibrils caused the terminals to develop α-syn inclusions, and 
that the inclusions later spread also to perikarya of the cells. The theory provides a 
reasonable explanation to why α-syn inclusions end up in glial cells which do not express 
the protein endogenously (Arima et al., 1998; Tu et al., 1998; Ahn et al., 2012; Amschl et al., 
2013). 
The oligomeric and fibrillar forms of the protein appear to be taken up through 
endocytosis and subjected to lysosomal degradation (Lee et al., 2008; Hansen et al., 2011; 
Steiner et al., 2011; Angot et al., 2012). However, lysosomes are not necessarily very effective 
in destroying aggregated or mutated α-syn (Cuervo et al., 2004; Rott et al., 2012). The 
monomeric form is suspected to incorporate itself into the cell membrane and pass through 
it, spread across the cytosol and escape the degradation by autophagocytosis (Lee et al., 
2008; Hansen et al., 2011, Steiner et al., 2011). It was recently reported that a single injection 
of pre-formed α-syn fibrils to dorsal striatum of wild-type mice evoked the spread of Lewy 
pathology, death of nigrostriatal DA neurons and motor deficits over a time course of 3 to 6 
months (Luk et al., 2012). Injection of the monomeric form of the protein was not reported 
to have neurodegenerative effects during the same period and expression of endogenous α-
syn was needed for the development of pathology. However, it is not known if the 
exocytosed and taken up protein is able to have the same effects on synaptic signaling as 
the recipient cell’s own endogenous α-syn.  
2.3.7 Putative treatment strategies targeting α-syn 
α-Syn has been considered as drug targets in synucleopathies and especially in PD 
(reviewed by Maguire-Zeiss, 2008). Prevention of α-syn misfolding and aggregation has 
been demonstrated to be protective in cell models (Outeiro et al., 2008; Sultana et al., 2011). 
siRNA mediated silencing of α-syn expression has also been postulated as a potential 
treatment (Lewis et al., 2008). Passive immunization is one interesting treatment strategy 
(Masliah et al., 2011), and antibodies specific to α-syn can prevent the intercellular 
transmission of α-syn aggregates (Bae et al., 2012). Antibodies specific for oligomeric and 
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protofibrillar α-syn are being developed (Fagerqvist et al. 2013). Furthermore, a clinical trial 
of active immunization with short α-syn resembling peptides is underway (Schneeberger et 
al., 2012).  
Naturally the α-syn targeting treatments, as any new therapies, are not without major 
concerns. The potential problem with passive immunization is that if it is used after the 
onset of symptoms, it may already be too late as a crucial amount of neurons will have been 
already lost, and the cascade of neurodegeneration involving also many other factors may 
still continue. It is not enough simply to create antibodies against α-syn, but the truly 
harmful forms of the protein should first be identified (Beyer et al., 2008; Bartels et al., 2011; 
Fagerqvist et al. 2013). Preventing α-syn misfolding and aggregation could be a valid 
strategy (Outeiro et al., 2008; Sultana et al., 2011), but achieving this with traditional small-
molecule compounds might prove difficult. Reducing the systemic amount of the protein 
with siRNA or immunization may have detrimental effects on the dopaminergic neurons 
(Gorbatyuk et al., 2010; Khodr et al., 2011) since native α-syn exerts its own neuroprotective 
role (Alves da Costa et al., 2002; Leng and Chuang, 2006; Quilty et al., 2006). Active 
immunization against the body’s own proteins also carries a threat of triggering 
autoimmune disease (Schneeberger et al., 2012). The protein may have important functions 
in synaptic plasticity, learning, motivation and control of movement. These functions can 
be compensated in knockout models where the protein has never existed in the first place, 
but it is not known what happens to these functions if the protein levels are suddenly 
dramatically reduced in adult individuals. Before reducing the systemic amount of the 
protein, its normal physiological functions need to be fully elucidated. 
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3 Aims 
The overall aim of this thesis work was to study the neuromodulatory effects by which α-
syn affects synaptic signaling in different scenarios. The more specific aims were as follows: 
1) To find possible link between differential α-syn expression, dopaminergic 
neurotransmission and genetic predisposition to drug abuse and alcoholism (Study I). 
One particular interest was α-syn and dopaminergic signaling in striatum of alcohol-
preferring rats. Striatum appears to be an important region for experiences of reward, as 
well as learning new preferences and behavioral patterns. Another focus was to 
examine if systemic ethanol would be able to affect the same pre-synaptic mechanisms 
of DA signaling as α-syn. 
2) To determine whether lack of α-syn in knockout mice would affect the cholinergic 
signaling in the neuromuscular junction by using electrophysiology and behavioral tests 
(Study II).  
3) To investigate if the lack of α-syn in knockout mice was able to affect neuronal 
excitability (Study III).  
4) To clarify whether locally applied, exogenous α-syn affected DA release and re-uptake 
in vivo (Study IV). 
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4 Materials and Methods 
4.1 ANIMALS 
4.1.1 ANA and AA rats (Study I) 
The ANA and AA rats used for study I were ethanol naïve, male and 3–5 months old. They 
were maintained at the National Laboratory Animal Centre (Kuopio, Finland; nowadays 
known as Lab Animal Centre) in an ambient temperature of 22–23°C and on 12/12 h 
dark/light cycle (lights on at 7 AM). Food and water were available ad libitum. The 
experiments on the rats were conducted according to the Council of Europe (Directive 
86/609) and Finnish guidelines, and approved by the State Provincial Office of Eastern 
Finland. 
4.1.2 Mice (Studies II-IV) 
The substrain of C57Bl/6J mice from Harlan Olac (Bicester, UK) has been found to carry a 
spontaneous deletion of the SNCA locus, in other words they are “natural” α-syn 
knockouts (Specht and Schoepfer, 2001). Here they are referred to as b6-. No compensatory 
up-regulation of - or -syn has been detected in the strain. The genomic deletion spans also 
to a neighbouring gene which codes multimerin 1, a protein expressed in platelets and 
endothelium that is involved in hemostasis (Specht and Schoepfer, 2004; Hayward, 1997). 
The most commonly used control for the b6- mice is the substrain of C57Bl/6J mice from 
Charles River Wiga (Sulzfeld, Germany) that express α-syn normally (Yavich et al., 2004; 
2005; 2006; Gureviciene et al., 2007; Chadchankar and Yavich, 2011; Chadchankar et al., 
2011; 2012). Here they are referred to as b6+. The b6- and b6+ mice have been bred 
separately for generations, and therefore any difference in their phenotype that is suspected 
to result from α-syn deletion needs to be verified using other models. The B6;129X1-
Sncatm1Rosl/J mice are a gene-targeted α-syn knockout line (Abeliovich et al., 2000). They were 
used in study II and they are referred to as b6-Ros. They originate from knockouts in F2 of 
129SV/j × C57/Bl6 hybrid mice that were originally created by Dr. Arnon Rosenthal. A 
breeding pair of these mice was obtained from the Jackson laboratory, cleaned by embryo 
transfer and bred in the Lab Animal Centre similarly as the b6+ and b6- mice. All mice used 
in these studies were males in the age range 8 to 25 weeks. Their general housing 
conditions were similar to those of the rats and their use had been sanctioned similarly as 
the rats (section 4.1.1). 
4.2 CONSTANT POTENTIAL AMPEROMETRY (STUDIES I AND IV) 
Stimulated DA release and re-uptake in the striatum were evaluated in vivo with constant 
potential amperometry (Fig. 5; Benoit-Marand et al., 2007). The animals were anesthesized 
and fixed in a stereotaxic frame (David Kopf, Tujunga, CA, USA) for the duration of the 
experiments. ANA and AA rats (study I) were anesthesized with urethane (1.4 g/kg i.p., 10 
ml/kg). b6+ and b6- mice (study IV) were anesthetized with chloral hydrate (420 mg/kg i.p., 
10 ml/kg) and the anesthesia was maintained with one quarter of the original dose every 
60-90 minutes. These anesthetics were chosen based on their minimal effects on 
dopaminergic synapses (Maggi and Meli, 1986; Lu and Greco, 2006). Local anesthesia was 
performed with s.c. injections of lidocaine (10 mg/ml), after which the skin and muscles 
were retracted, the skull was exposed and drilled to allow the insertions of working, 
stimulating and auxiliary electrodes. The auxiliary electrode (stainless steel screw) was 
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placed in the skull behind lambda, and the reference electrode (silver/silver chloride) was 
placed against the exposed skull which was always covered by a layer of saline. The 
working electrode was positioned in the striatum and the stimulating electrode in the 
medial forebrain bundle at the level of lateral hypothalamus. The coordinates for the 
electrode postitions in relation to bregma and the skull surface were obtained from rat 
(Paxinos and Watson, 1986) and mouse (Franklin and Paxinos, 2007) brain atlases. The exact 
position of the stimulating electrode was determined from the maximal DA overflow in 
response to stimulation.  
The working electrode was a single carbon fiber with a diameter of 30 µm (World 
Precision Instruments, Sarasota, FL, USA) fixed with epoxy glue inside a glass capillary. 
Then, 350 ± 50 µm of the tip of the fiber was exposed from the capillary. A custom-built 
three-electrode potentiostat maintained the working electrode at 0.4 V versus a silver/silver 
chloride reference electrode, which is sufficient to cause the near complete oxidation of DA 
(Dugast et al., 1994). Data were digitized at 1 kHz and stored in a computer using Invilog 
Voltammetry System (Invilog Research, Kuopio, Finland). The exact sensitivity of 
individual working electrodes had been measured beforehand in an unstirred solution with 
1, 2 and 3 µM of DA in the presence of 200 µM of ascorbic acid. Ascorbic acid was included 
in the calibration solution since it is electrochemically active and present in the brain at 
concentrations of 200-300 µM (Basse-Tomusk and Rebec, 1991). No post-calibrations of the 
working electrodes were performed because in some animals the electrodes were used for 
electrolytic marking of their positions within striatum. The actual measurements were 
always started 1.5 h after lowering the working electrode into the brain, since carbon fiber 
electrodes lose sensitivity exponentially during this time (Michael et al., 1987). If the 
working electrode was moved within striatum, it was allowed to remain for 10-12 min in its 
new position before performing measurements in order to allow the baseline signal to 
stabilize. 
The stimulating electrode was a bipolar tungsten wire with diameter of 350 µm. Biphasic 
constant current pulses (1 ms each polarity) were applied on the tungsten electrode from a 
battery-operated constant current unit (A365; World Precision Instruments) controlled by 
the Invilog Voltammery System through a personal computer. In ANA and AA rats (study 
I) DA overflow was evoked with 400 µA pulses delivered in 20 (5 s) and 50 Hz (2 s) 
frequencies. The interval between the 20 and 50 Hz stimulations was 3 min. In b6+ and b6- 
mice (study IV), 10 (5s), 20 (2 s), 30 (2s) and 50 Hz (2s) stimulations were used and the 
current of the pulses was 180 µA. The interval between stimulations of different frequency 
increased from 1-2 min to 3-4 min as the frequency of the stimulations increased in order to 
prevent exhaustion of the DA stores. 
In AA and ANA rats (study I), the responses to the stimulations were measured from 
three different structures in the striatum; CPu, AcbC and AcbSh. The working electrode 
was lowered from 1.8 mm lateral and 1.6 mm anterior to bregma to depths of 5.5 mm 
(CPu), 7.2 mm (AcbC) and 8.3 mm (AcbSh) from the skull surface. An additional set of 
stimulations (20 and 50 Hz) was applied 12 min after the first stimulation to ensure a stable 
DA overflow when the working electrode was in its most ventral position in the AcbSh. 
Immediately after this second measurement, the rats were injected i.p. with a 0.1 g/kg dose 
of 10 % (v/v) ethanol. Evoked DA overflow was measured 15, 30, 45 and 60 min after the 
injection. After the last measurement, a 3g/kg dose of 50 % (v/v) ethanol was injected and 
measurements of evoked DA overflow were conducted again with 15 min intervals for 1 h 
after the treatment. It should be recalled that 0.1 g/kg of ethanol is a very small dose that is 
eliminated rapidly, whereas 3 g/kg is a very large, hypnotic-sedative dose (Lopez-Jimenez 
et al., 2013). 
The exact stimulation and measurement protocols in b6+ and b6- mice (study IV) are 
described in section 4.5. Electrolytic lesions were made via the working electrodes (6 V, 15 s 
for rats and 5 s for mice) when the lesions did not interfere with following tissue analysis. 
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Brains were removed, frozen and cut with a microtome for histological analysis. In some 
rats, striatal structures were dissected, frozen and used for western blot analysis. 
 
Figure 5. Schematic presentation of the setup for constant potential amperometry. Constant 
potential (U) which is sufficient to oxidise dopamine is applied to the working electrode. The 
oxidation reaction causes a change of the Faradaic current of the working electrode (I) which 
is directly proportional to the concentration of dopamine. The current is transformed to voltage 
by the head stage, digitized by digital-to-analog converter and stored on a hard drive for further 
analysis. The potential of the working electrode is maintained by means of potentiostat with its 
reference and auxiliary electrodes. Stimulation (S) is applied through the stimulating electode to 
the dopaminergic axons, which results in measurable changes in DA concentration near the 
dopaminergic terminals. The changes in concentration are detected practically in real time 
(Benoit-Marand et al., 2007). 
4.3 ELECTROMYOGRAPHY (STUDY II) 
Repetitive electrical stimulation and electromyography were used to measure the 
functionality of the neuromuscular junction in b6+, b6- and b6-Ros mice (Fig. 6). The 
animals were anesthetized with chloral hydrate (450 mg/kg i.p., 10 ml/kg) and the 
anesthesia was sustained by injecting one quarter of the initial dose after every 45-60 min. 
The animals were fixed to a heated stand by their limbs and tail using tape. The electrodes 
were 26-gauge injection needles made from stainless steel. Their exact positions in relation 
to each other are indicated in fig. 6. The two stimulating electrodes were placed against the 
caudal motor axons at the base of the tail. The recording and reference electrodes were 
inserted into the caudal muscles on the lateral side of the tail. The ground electrode was 
implanted under the skin at the back of the mouse. 
Sub-maximal electrical stimuli, 2–3 mA in amplitudes, were produced using an A320 
current isolation unit (World Precision Instruments). Master-8 pulse stimulator (A.M.P.I., 
Jerusalem, Israel) was used to set the pulse length (0.1 ms) and intervals (10–300 ms). DAM 
70 Differential Amplifier (World Precision Instruments) amplified and filtered (300 Hz to 3 
kHz) the signals, which were transferred to a personal computer using Digidata 1321A 
analog-digital converter and Clampex 8.2 software (Axon Instruments, Sunnyvale, CA, 
USA). The sampling rate was 10 kHz. Five trains of six pulses, each at different between-
pulses intervals, were used to stimulate the caudal motor axons. The intervals between 
pulses were 300, 100, 50, 20 and 10 ms, and data were collected over a period of 2 s. Each 
stimulation train was repeated three times per mouse with a 1 min pause after each train. 
The anesthesized animals were sacrificed after the measurements. 
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Figure 6. Schematic presentation of the electromyography setup. Electrical stimulation of the 
tail’s motor axons causes the lower motor neurons to release acetylcholine at the 
neuromuscular junction. This produces compound muscle action potentials (CMAPs) at the 
muscles of the tail which can be measured using electromyography. The example shows six 
CMAPs acquired from a b6-Ros mouse using a stimulation train with 300ms intervals between 
stimulation pulses (for more detailed visualization of the CMAPs, see figure 10 A). Method was 
adapted from Boërio et al., 2009. 
4.4 DIRECT CURRENT POTENTIAL RECORDING (STUDY III) 
CSD was initiated with single pulse electrical stimulation and measured with DC potential 
recording in b6+ and b6- mice (Fig. 7). The mice were anaesthetized with chloral hydrate 
(420 mg/kg i.p., 10 ml/kg) and fixed in a stereotaxic frame (David Kopf). Anaesthesia was 
maintained with one sixth of the original dose administered every 45–60 min. The skin and 
muscles were retracted, the skull was exposed and trepanations for the working and 
stimulating electrodes were made to the positions indicated in Fig. 7 without puncturing 
the dura mater. The recordings were made with two miniature silver/silver chloride 
electrodes (Invilog Research, Kuopio, Finland) in plastic capillaries (0.5 mm in diameter) 
filled with 2% (w/v) gelatin in saline. The two electrodes are referred to as channels 1 and 2. 
The tips of the capillaries were lowered 0.3 mm down from the skull surface against the 
dura. The current was recorded against a silver/silver chloride reference electrode. A 26 G 
stainless steel needle functioned as the ground electrode and it was punctured through the 
skin at the back of the mouse. The stimulating electrode was a tungsten bi-wire with two 
ball-shaped tips in a distance of 1.5 mm from each other (Invilog Research), and it was 
lowered on the dura 0.4 mm from the skull surface. 
The DC potential recording was performed using a Model 440 Instrumentation 
Amplifier (Brownle Precision Co., Palo Alto, CA, USA). The method measured changes  in 
the potential in the DC mode, meaning that there was no highpass filter in use (Peeters et 
al., 2007; for review, see Eikermann-Haerter et al., 2012). The low-pass filter was set to 100 
Hz. Data were digitized at 1000 Hz with a Digidata 1321A analog-digital converter and the 
program Clampex 8.2 (Axon Instruments). The stimulation pulses were produced with a 
type 215/I stimulator (Hugo Sachs Elektronik - Harvard Apparatus GmbH, March-
Hugstetten, Germany) and transmitted to the electrodes through a SIU5 Stimulus Isolation 
Unit (Grass Technologies, West Warwick, RI). The pulse width was set at 0.1 s.  
The stimulating electrode was placed on the dura and was always covered by a layer of 
saline on the skull, and thus a field stimulation approach was used, and data on threshold 
is expressed as voltage. The CSD threshold was determined by applying electrical pulses 
with intervals of 100 s and at increasing voltage. The voltage of the first pulse was 10 V, the 
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increment from pulse to pulse 10 V and the maximal stimulation intensity 100 V. The 
stimulations for evoking CSD were done twice. In order to make sure that the surgical 
procedures did not cause CSD, baseline signal was recorded for 30 min before and between 
stimulations and 15 min after. The anesthesized animals were sacrificed after the 
experiments. 
 
Figure 7. Schematic presentation of the direct current potential recording setup. The positions of 
trepanations are indicated with black circles and the dashed circle indicates the position of the 
reference electrode. Ch1 (channel 1) and Ch2 (channel 2) refer to the working electrodes. The 
ground electrode was punctured through the skin in the back of the mouse. The example data 
shows a typical recording with artefacts of stimulation and the cortical spreading depression 
(CSD) waves. 
4.5 MICROINJECTION (STUDY IV) 
For studying the delayed effects of exogenous α-syn on DA overflow, the protein was 
injected into the DS of b6+ and b6- mice and constant potential amperometry was 
performed six days later (Fig. 8 A). Stock solution of monomeric Alexa Fluor 488–labeled α-
syn protein (1 µg/µl, 30 mM Tris-HCl and 325 mM NaCl, pH 7.5; provided by H. Lundbeck 
A/S, Valby, Denmark) was diluted to a concentration of 0.1 µg/µl with phosphate buffered 
saline (0.1 M, pH 7.4). Mice were anesthetized with a medetomidine-ketamine mixture (0.6 
mg ⁄ kg and 45 mg ⁄ kg i.p. respectively, 5 ml/kg) and fixed into a stereotaxic frame (David 
Kopf). Local anaesthesia was performed with s.c. injections of lidocaine (10 mg/ml). 
Microinjections were performed using glass capillaries with a tip diameter of 40 µm. 
Animals were injected into the dorsal striatum with 0.1 µg of α-syn protein over a period of 
17 min. The needle was kept in place for an additional 15 min after the flow of liquid was 
stopped. A similar injection with diluent only was performed to the contralateral 
hemisphere. The injections were performed at the following coordinates respective to 
bregma: anterior +1.4 mm; lateral ± 1.3 mm; ventral -3.3 mm (Franklin and Paxinos, 2007). 
Post-operative care was sought to according to the general instructions of the lab animal 
centre and the mice were single housed until the measurements of stimulated DA overflow 
were performed six days later. For these measurements, the mice were anesthesized and 
fixed to the frame as described earlier (section 4.2). The working electrode was lowered into 
the dorsal striatum at an angle of 16 ° from vertical at coordinates 1.4 anterior and ± 2.1 
lateral to bregma. The ventral positions of the electrode are described in Fig. 8 A. DA 
overflow was evoked at each position of the working electrode with 50 Hz stimulation, 
except at the depth of -3.3 mm where also 10, 20 and 30 Hz stimulations were applied. After 
31 
 
 
the measurements, the anesthesized mice were sacrificed, their brains removed, immersion-
fixed in 4 % (w/v) paraformaldehyde in phosphate buffered saline for 36 h (+4 °C) and 
stored in phosphate buffered saline containing 0.02 % (w/v) Na-azide (+4 °C). 
 
Figure 8. Schematic presentation of the positions of the microinjection capillaries and the 
working electrodes in the measurement of delayed (A) and immediate (B) effects of α-syn 
microinjection. 
Only b6- mice were used for studying the immediate effects of the protein, and the 
microinjections and constant potential amperomery were performed during the same 
surgical procedure (Fig. 8 B). The tip of the microinjection capillary was fixed to a distance 
of 46 ± 3 µm from the center of the working electrode using epoxy glue. This assembly was 
lowered into the brain (1.4 mm anterior, 1.3 mm lateral and 3.3 ventral from bregma) where 
it was kept for the entire duration of the experiment. The injection of protein (monomeric 
human recombinant α-syn, 1 µg/µl, Nordic Biosite, Täby, Sweden) or diluent (20 mM Tris-
HCl [pH 7.5], 0.1 M NaCl, 1mM MgCl₂) was made immediately after the pre-injection 
stimulations. The amount of injected protein was 2 µg and the injection time was 20 min. 
Responses to 10, 20, 30 and 50 Hz stimulations were measured before and after the 
microinjection. The post-injection stimulations were repeated every 30 min for 3 h. The 
animals were sacrificed after the experiment and their brains stored as described above. 
4.6 BEHAVIORAL TESTING (STUDY II) 
4.6.1 Rotarod 
The motor coordination and balance in b6+, b6- and b6-Ros mice were analyzed using an 
accelerating Rotarod (Ugo Basile, Comerio, Italy). The animals were allowed accustom 
themselves with the device for 1 min before testing, 30 s on a motionless bar and 30 s on a 
bar that was rotating at minimal speed (4 rpm). After this adaptation period, the apparatus 
was set to accelerate (from 4 to 40 rpm) and timing was started. The time that the animals 
were able to run on the rotating bar without falling down from the rod was recorded. The 
mouse could grab hold on the bar for one or two consecutive turns, but after the third 
consecutive turn the animal was removed from the rod. The maximum time that the 
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animals were allowed to remain on the rod was 480 s (8 min). The test was repeated three 
times at two day intervals. 
4.6.2 Grip strength 
Neuromuscular function in b6+, b6- and b6-Ros mice was assessed by measuring the front 
paw grip strength. The animals were positioned on a normal home cage roof with parallel 
round metal bars (2 mm in diameter and 7 mm from each other). The animals were 
confined to a space of 15 x 18 cm with 10 cm high plastic walls. The animal’s tail was taped 
tightly to a calibrated spring which could be raised upwards at a steady speed. Before the 
actual testing, the animals were allowed to familiarize themselves with the surroundings 
for 30 s and one or two rehearsal lifts were performed to make sure that the animals 
grabbed the bars. During the actual measuring the animals were lifted so that they were 
able to grab the bars only with their front paws. When lifting, the apparatus added 0.95 
Newtons of force per second. The maximal force the animals were able to grab against the 
bars against was recorded. Three measurements were conducted per animal from which an 
average was calculated. The apparatus was cleaned in the same way as the Rotarod 
between animals. The results were calculated as force per unit of body mass (N/kg). 
4.6.3 Footprint pattern 
The gait of b6+, b6- and b6-Ros mice was assessed with a footprint pattern test. The front 
paws of the animals were dipped in red nontoxic ink and the hind paws in blue nontoxic 
ink. The animals were placed at the brightly lit end of a transparent tunnel that had its 
bottom lined with paper. At the far end of the tunnel there was a dark cylinder with some 
home cage bedding. The animals walked through the tunnel so that consecutive steps could 
be recorded without the animal turning back or stopping too often. A consecutive step pair 
was chosen from each animal for analysis, excluding the first and last recorded steps. Fore- 
and hindpaw stride length, hind- and front base width between left and right paws and 
forepaw/hindpaw overlap were measured. The tunnel was cleaned after each individual 
animal. 
4.7 WESTERN BLOT (STUDY I) 
The tissue samples from the striatum of ANA and AA rats were mechanically homogenized 
in 150 µl of Dulbecco’s phosphate-buffered saline (Invitrogen, Carlsbad, CA, USA). Protein 
degradation was prevented with proteinase (100× cocktail; Thermo Scientific, Waltham, MA, 
USA) and phosphatase inhibitors (Halt phosphatase inhibitor; Thermo Scientific). Fifty µl of 
the tissue homogenate was mixed with an equal volume of protein extraction detergent (T-
PER, Pierce, Rockford, IL, USA) in order to extract also the membrane bound proteins. The 
remaining membrane particles were separated from the protein fraction by incubating the 
samples on ice for 10 min and by centrifugating with 15700 g for 10 min at +4 °C. Total 
protein concentration was measured with BCA Protein Assay Kit (Thermo Scientific). The 
separation of the proteins in the sample was achieved by loading 30 µg of total protein 
which was run on 4–12 % sodium dodecyl sulphate–page gels (NuPAGE 4–12% BT 1.5; 
Invitrogen). The proteins were then transferred from the gels to polyvinylidene difluoride-
membranes (Hybond-P; Amersham Bio-sciences, Amersham Place, UK) using a semi-dry 
electro-transfer apparatus (TE77 ECL-semidry Transfer unit, Amersham Biosciences). The 
membranes were blocked with 5% (v/v) milk powder in Tris-buffered saline with 0.05% 
Tween-20 (TBST) and then incubated in primary α-syn antibody (ab6162, 1:1000 dilution; 
Abcam, Cambridge, UK) overnight with rotation at +4°C. The membrane was washed for 4 
× 10 min with TBST, incubated in horseradish peroxidase-labelled secondary antibody 
(ab6900, 1:15000 dilution; Abcam) for 1 h with rotation at +4°C and washed as before. 
Depending on the properties of the individual membrane, either ECL+ or ECL Advance 
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reagent (Amersham Biosciences) were used to visualize the horseradish peroxidase-label in 
the secondary antibody. The membranes were photographed with ImageQuant RT ECL-
camera (GE healthcare, Buckinghamshire, UK). The α-syn antibody recognized a specific 
band at ~13 kDa. The membranes were stripped from the antibodies using Restore Western 
Blot Stripping Buffer (Thermo Scientific) after imaging and milk blocked as before. 
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was used as the control protein and 
it was detected using specific primary (ab8245, 1:15000 dilution; Abcam) and secondary 
(NA931V, 1:12000 dilution; Amersham Biosciences) antibodies. 
4.8 IMMUNOHISTOCHEMISTRY (STUDY IV) 
The brains of α-syn and/or diluent injected b6+ and b6- were cut into 35 μm coronal 
sections with a freezing-sliding microtome. The sections were immunostained by free 
floating technique. They were first heat treated at +80 °C in 0.05 M Na-citrate for 30 min in 
order to reveal the antigen, and blocked in 1% bovine serum albumin (BSA) for 1 h. The 
solution used for diluting the BSA and antibodies, and for rinsing the sections between 
treatments (3 × 5 min) was 0.5 M Tris buffered saline (pH 7.6) with 0.5% of Triton X-100. 
The sections were transferred to a solution containing the primary rabbit antibody against 
human α-syn (SA 3400, Enzo Life Sciences, Farmingdale, NY, USA, 1:1000 dilution) for 
overnight incubation on a shaker table. After this, the sections were transferred for 2 h to a 
solution containing a biotinylated secondary antibody (BA-1000 anti-rabbit IgG, Vector 
Labs, Burlingame, CA, USA, 1:500 dilution), and for 2 h to a solution containing 
streptavidin-horseradish peroxidase (RPN1231V; GE Healthcare, Little Chalfront 
Buckinghamshire, UK, 1:1000 dilution). Following rinsing, the sections were incubated for 3 
min in 3,3-diaminobenzine tetrahydrochloride for making the horseradish peroxidase label 
visible. The stained sections were mounted on slides and coverslipped. 
4.9 DATA ANALYSIS 
When studying DA overflow data, it should be remembered that peak concentration of DA 
after stimulation does not reflect only DA release, but also the effectiveness of re-uptake can 
affect the maximal concentration, and that maximal velocity of DA re-uptake can be reliably 
assessed only after release which is sufficient to saturate the DAT (Wightman and 
Zimmerman, 1990; Benoit-Marand et al., 2007). In study I, the peak levels of evoked DA 
overflow were calculated in molar concentrations (μM) or as a percentage of peak overflow 
before ethanol administration. Constant potential amperometry can follow the changes in 
extracellular DA concentration in real time and makes it possible to evaluate DA re-uptake 
from the downward slope of the DA overflow curve. The slope was approximated by non-
linear regression following the equation y(x)= y0 · ekx. The fit was performed using the 
software package StimFit 0.8.15 (University of Fribourg, Fribourg, Switzerland). In the 
equation, a high value of k represents a faster disappearance of DA from the extracellular 
space.  
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In the western blot analysis in study I, the intensities of the α-syn and control protein 
bands were measured using Quantity One software (Bio-Rad, Hercules, CA, USA). Samples 
were divided into random ANA–AA pairs so that the comparable samples were placed on 
the same membrane. The percentage of α-syn band intensity from that of the control 
protein was calculated for each sample. ANA values were chosen as the baseline. 
The electromyography data in study II and DC potential recording data in study III were 
analyzed off-line with Clampfit, version 8.2 (Axon Instruments).  
By the time that study IV was conducted a more sophisticated custom-made software for 
analyzing DA overflow data was available in our lab. The results given by the program are 
based on the principles described below. The extracellular DA levels in the terminal fields 
after brief electrical stimulation are a result of the balance between release and re-uptake 
and can be described by the following Michaelis-Menten equation (Wightman and 
Zimmerman, 1990): d[DA]/dt = [DA]p * f – Vmax/ (Km/[DA] + 1). In the equation, [DA] 
represents instantaneous DA concentration, d[DA]/dt the rate of re-uptake, [DA]p the DA 
release per stimulus pulse, f is the frequency of stimulation, and Vmax and Km refer to the 
maximal rate of re-uptake and apparent affinity, respectively. After the end of stimulation, 
the release component is absent and the change in DA concentration can be described by 
another equation: d[DA]/dt = -Vmax/(Km/[DA] +1). The custom made software solves both 
these equations, and determines [DA]p,  Vmax and Km providing the best fit between 
experimental data and the data simulated by the model. 
4.10 STATISTICAL ANALYSIS 
Statistical analysis was performed using the statistical tools of Prism 5 for Windows 
(GraphPad Software Inc., San Diego, CA, USA), and IBM SPSS Statistics 19 and its earlier 
versions (IBM Corporation, Armonk, NY, USA). In study I, differences between ANA and 
AA rats in absolute levels of peak DA overflow, α-syn expression and the value of k 
(representing rate of re-uptake) were evaluated with unpaired, two-tailed Student’s t-test. 
Peak DA overflow and k were evaluated also with ANOVA for repeated measures, as were 
also the effects of ethanol on evoked DA overflow. In study II, the Rotarod results were 
evaluated with ANOVA for repeated measures while other results were evaluated with 
one-way ANOVA. Bonferoni’s test was used in the post hoc analysis. In study III, the results 
on CSD initiation and propagation were evaluated with ANOVA for repeated measures. In 
study IV, ANOVA for repeated measures was used for evaluating data from measurements 
which were performed repeatedly in a single position in the striatum. Otherwise two-way 
ANOVA was used. Post hoc analysis was performed with unpaired, two-tailed Student’s t-
test since it is capable of comparing only two groups. The error bars in all results signify 
standard error of mean. 
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5 Results 
5.1 STIMULATED DOPAMINE OVERFLOW AND α-SYN EXPRESSION IN 
THE STRIATUM OF ANA AND AA RATS (STUDY I) 
 
 
 
 
Figure 9. Stimulated dopamine (DA) overflow, re-uptake and -syn expression in striatum of 
ANA and AA rats (Study I). A: DA overflow in the caudate putamen (CPu), nucleus accumbens 
core (AcbC) and nucleus accumbens shell (AcbSh) in ANA and AA rats in response to 50 Hz 
stimulations of the medial forebrain bundle. nANA = 6–8 and nAA = 7–8. B: Re-uptake of DA 
(represented by the value of k) was determined from the right-sided slope of the DA overflow 
curve following stimulation at 50 Hz in the CPu, AcbC and AcbSh. C: Comparison of -syn 
expression between AA and ANA rats in the CPu, AcbC and AcbSh (n = 4). * designates p < 
0.05 (t-test) 
Constant potential amperometry revealed no differences in the parameters of stimulated 
DA overflow between ANA and AA rats when examining the striatum as a whole. 
However, peak DA overflow after 50 Hz stimulation was lower and re-uptake faster in AA 
rats in comparison to ANA rats when concentrating AcbC alone (Fig. 9 A and B, ). Data 
from 20 Hz stimulations confirmed the result on peak DA overflow but not on re-uptake 
(Study I, table 1) suggesting that the reduction in peak DA overflow was not entirely due to 
more efficient re-uptake. When comparing α-syn expression in the same structures with 
western blot, no differences were seen in the CPu or AcbSh, but it was found that in the 
AcbC AA rats exhibited higher expression than the ANA rats (Fig. 9 C). No differences 
were seen between the rat lines in stimulated DA overflow after the ethanol injections 
(study I, Fig. 3). The results suggest that increased α-syn expression in specific regions is 
associated with decreased DA release and more efficient re-uptake, and that these factors in 
the AcbC may predispose an individual to substance abuse. 
5.2 EXCITABILTY OF SKELETAL MUSCLES AND MOTOR PERFORMANCE 
IN WILD-TYPE AND α-SYN DEFICIENT MICE (STUDY II) 
No α-syn dependent differences were seen in the amplitudes of compound muscle action 
potentials (CMAPs) in response to repetitive stimulation, but instead, repetitive CMAPs (R-
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CMAPs, Fig. 10 A) were detected in 4 out of 5 b6- mice and 3 out of 5 b6-Ros mice, while 
only 1 out of 5 b6+ mice displayed a single R-CMAP (Fig. 10 B). The R-CMAPs were 
typically detected in α-syn deficient mice after the first pulse (39.5 % of all R-CMAPs). Next 
it was tested whether this abnormality would reflect a defect in motor control. The α-syn 
deficient mice performed initially worse in the Rotarod test, but they were able to improve 
their performance as the test was repeated so that all three lines were indistinguishable by 
the third day of testing (Fig. 10 C; training × genotype interaction F(4, 30) = 3.2, p = 0.026). 
The time spent running on the rod was significantly different between the three lines (F(2, 
15) = 10.5, p = 0.020) but post hoc analysis revealed a significant difference only between b6+ 
and b6-Ros mice (p = 0.003) and between b6- and b6-Ros mice (p = 0.004). b6+ and b6- mice 
were able to stay on the non-slippery rod of the Rotarod apparatus during a full turn but in 
contrast to this behavior, b6-Ros mice could not cling on to the rod and dropped off. 
Clinging on to the bar was seen in 83% of all trials with b6+ mice, 89% with b6- mice but 
only in 6% with b6-Ros mice. This was not due to any deficiency in muscle strength or 
control of ambulation, since the results of the grip strength and footprint pattern tests were 
the same in all three lines (study II, Fig. 2 B and table 1). The occurrence of R-CMAPs in b6- 
and b6-Ros mice suggests that the lack of α-syn influences the excitability of muscles. 
However, the effect is not strong enough to cause any major motor dysfunction. The slow 
improvement of b6- and b6-Ros mice to the level of b6+ mice in the Rotarod test suggests 
that lack of α-syn causes a disability in motor learning. 
 
 
 
Figure 10. Occurrence of repetitive compound muscle action potentials (R-CMAPs) and 
performance of the -syn deficient (b6- and b6-Ros) and wild-type (b6+) mice in the Rotarod 
test (Study II). A: Example of a train with 300 ms intervals between pulses from a b6-Ros 
mouse showing a R-CMAP after the first pulse. The inset shows the artifact of stimulation (the 
first small peak), the primary compound musle action potential (CMAP) and three late 
components. B: Number of detected R-CMAPs with different amounts of late components (n = 
5). C: The Rotarod test was repeated three times every third day (n = 6). 
5.3 INITIATION AND PROPAGATION OF CORTICAL SPREADING 
DEPRESSION IN WILDTYPE AND α-SYN DEFICIENT MICE (STUDY III) 
CSD did not differ between b6+ and b6- mice in any of the analyzed parameters (Fig. 11), 
nor was there any interaction between genotype and stimulation or channel. No 
spontaneously occurring CSD waves were detected in the recordings. The average speed of 
the CSD wave was 2.1 mm/min. The results suggest that the lack of α-syn does not effect 
the initiation or propagation of CSD. 
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Figure 11. Properties of cortical spreading depression (CSD) waves in wild-type (b6+, n = 5) 
and -syn deficient (b6-, n = 6) mice (Study III). A: Threshold of CSD in the two mouse lines. 
St1 refers to stimulation 1 and St2 to stimulation 2. B: Propagation speed of the CSD wave. C: 
Rising speed of the CSD wave measured from the left slope. Ch1 stands for channel 1 and Ch2 
for channel 2. D: Peak amplitudes of the waves. 
5.4 DELAYED EFFECTS OF α-SYN MICROINJECTION ON STIMULATED 
DOPAMINE OVERFLOW IN WILD-TYPE AND α-SYN DEFICIENT MICE 
(STUDY IV) 
 
Human α-syn could not be detected from the striata of mice six days after microinjection 
(Fig. 12 A-D), even though some difference in staining could be seen between control and 
α-syn injected hemispheres in b6+ mice (Fig. 12 C). Nonetheless, there was a general trend 
for reduced peak DA overflow and maximal velocity of DA re-uptake in the α-syn injected 
mice (Fig. 12 E-J). The reduction in stimulated DA overflow in response to 50 Hz 
stimulations was significant in b6- mice [Fig. 12 H, F(1,57) = 9.0, p = 0.004]. The post hoc 
analysis revealed a significant difference only at a depth of -3.9 mm. No significant changes 
were seen in b6+ mice (Fig. 12 G). The peak amplitudes of DA overflow after 50 Hz 
stimulations were different between b6+ and b6- mice after control treatment (F[1,57] = 4.7, 
p = 0.034) but because the damage from the control treatment alone may affect the 
dopaminergic tone in the region, these results should not be used to draw conclusions on 
the intrinsic differences between the mouse lines.  The effect of α-syn microinjection on DA 
overflow after 10, 20, 30 and 50 Hz stimulations at depth -3.3 mm was not statistically 
significant (Fig. 12 E-H,  F[1,20] = 2.1, p = 0.165). 
The injection of α-syn decreased Vmax when examining all data from b6+ and b6- mice 
(Fig. 12 I and J, F[1,129] = 14.26, p < 0.001). The effect remained significant when looking at 
b6+ (Fig. 12 I, F[1,60] = 4.4, p = 0.040) or b6- (Fig. 12 J, F[1,57] = 10.3, p = 0.002) mice alone. 
The post hoc analysis revealed a significant difference only at a depth of -3.0 mm in the b6- 
mice. Vmax was significantly different between b6+ and b6- mice after control treatment 
(F[1,57] = 4.8, p = 0.033). There were no significant differences in Km (Fig. 12 I and J, insets) 
resulting from genotype, treatment or their interaction. The results indicate that exogenous 
α-syn is capable of causing changes in pre-synaptic DA release and re-uptake six days after 
microinjection even though α-syn itself is no longer present at the pre-synaptic terminals in 
any detectable amounts. 
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Figure 12. Delayed effects of -syn microinjection in b6+ and b6- mice (Study IV). A, B: 
Sections showing the control-injected (left) and -syn-injected (right) hemispheres of b6+ (A) 
and b6- (B) after staining with an antibody specific for human α-syn. The tracks of the 
voltammetry electrode are visible in the hemispheres. The magnified areas shown in C and D 
are indicated with the white, dashed rectangles in A and B, respectively. E, F: Dopamine (DA) 
release in response to 10, 20 and 30 Hz stimulations was measured at a depth of -3.3 mm in 
the ventral striatum of b6+ (E) and b6- (F) mice. n = 6 per group. G, H: DA overflow in 
response to 2 s, 50 Hz stimulation was measured in six different positions in the striatum of 
b6+ (G) and b6- (H) mice. Maximal velocities of DA re-uptake (Vmax) in b6+ (I) and b6- (J) 
mice were calculated from the DA peaks after 50 Hz stimulations. The Km values, (insets in I 
and J) describing the affinity of DAT, were calculated from the DA peaks after 30 Hz 
stimulations. * designates p < 0.05 in the post hoc analysis (t-test) 
5.5 IMMEDIATE EFFECTS OF α-SYN MICROINJECTION ON STIMULATED 
DOPAMINE OVERFLOW IN α-SYN DEFICIENT MICE (STUDY IV) 
Since it was not possible to detect the injected α-syn protein from the striatum six days after 
microinjection, (Fig. 12 A-C), it was decided to inject a larger dose of the protein into b6- 
mice and to measure the effects on stimulated DA overflow immediately (Fig. 13). As a 
result, the injected α-syn was seen to have diffused around the injection site (Fig. 13 E), and 
α-syn accumulating cell bodies were also detected (Fig. 13 F). In contrast to the delayed 
effects of α-syn microinjection (Fig. 12), the immediate effects included a trend for increased 
peak DA overflow, especially after low frequency stimulations (Fig. 13 A-D), and an 
increase in maximal velocity of DA re-uptake (Fig. 13 H). There was also a trend for 
increase in the value of Km (Fig. 13 G). However, the effects did not reach statistical 
significance, not even the overall interaction between stimulation frequency, time and 
treatment in peak DA overflow [F(1.8,10.7) = 2.8, p = 0.112]. Some of the effects could be 
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seen even before the actual injection (Fig. 13 A, B, G, H) indicating that the protein had 
leaked from the tip of the electrode-capillary assembly during the 1.5 h period that the 
electrode had to stay in the brain before measurements (see section 4.3). 
 
Figure 13. Immediate effects of -syn microinjection in b6- mice (Study IV). A-D: Dopamine 
(DA) release was measured in response to 10 (A), 20 (B), 30 (C) and 50 Hz (D) stimulations of 
the medial forebrain bundle. n = 5 per group. The black arrow indicates when the microinjection 
pump was turned on. E: Section showing the non-injected (left) and α-syn-injected (right) 
hemispheres after staining with an antibody specific for human -syn. The track of the 
microinjection capillary-voltammetry electrode -assembly is visible in the right hemisphere. F: 
The area shown in F is indicated with the white, dashed rectangle in E.  Individual cells stained 
by the -syn antibody are indicated with white arrows. G: The Km values were calculated from 
the DA peaks after 30 Hz stimulations. H: Maximal velocities of DA re-uptake (Vmax) were 
calculated from the DA peaks after 50 Hz stimulations 
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6 Discussion 
6.1 STIMULATED DOPAMINE OVERFLOW AND α-SYN EXPRESSION IN 
THE NUCLEUS ACCUMBENS CORE DIFFERENTIATE ANA AND AA RATS 
(STUDY I) 
In the first part of this work (study I) the presynaptic DA release and re-uptake along with 
α-syn expression were studied in the striatum of two rat lines that have been bred for 
differential ethanol consumption (Fig. 9). The result that higher α-syn expression was 
found in the AcbC of the ethanol preferring AA rats is in line with the results from human 
subjects and other animal models which show that high α-syn expression is associated with 
substance abuse (Mash et al., 2003; Bönsch et al., 2005a; b). Substance abuse  can cause α-syn 
expression to increase (Brenz Verca et al. 2005); this might be due to disinhibition of 
transcription as cocaine abusers have a low expression of NURR1 (Bannon et al., 2002) 
which downregulates SNCA expression (Yang and Latchman, 2008). Cocaine abusers also 
display decreased expression of striatal VMAT2 (Little et al., 2003) which may be a 
downstream effect of the increased α-syn expression (Mash et al., 2003; Guo et al., 2008; 
Fountaine et al., 2008). The current results concur with other reports which suggest that 
increased α-syn expression can also contribute to vulnerability to substance abuse (Liang et 
al., 2003; Boyer and Dreyer, 2007). An increased α-syn level may be a part of a vicious cycle 
which leads to addiction by modulating the neurotransmitter tone in certain areas of the 
brain to a state where an individual experiences heightened drug craving (Bönsch et al., 
2005a; Mash et al., 2008; del Castillo et al., 2009). 
The localization of expressional and functional differences between ANA and AA rats to 
AcbC concurs with the reports which show that increased drug self-administration and 
drug-seeking is associated with increased α-syn expression in this area (Boyer and Dreyer, 
2007; del Castillo et al., 2009). However, it was reported by Liang et al. (2003) that the 
differences in α-syn expression between the alcohol preferring (P) and non-preferring (nP)  
rats were localized to the hippocampus and CPu (DS), while the expression in the AcbC 
was identical. This could indicate that the differential ethanol consumption in these line 
pairs is driven by slightly different behavioral mechanisms, as DA release in the AcbC is 
essential for motivation of effort requiring actions and the CPu drives more automated, 
habitual behavior (Yin et al., 2004; Salamone and Correa, 2012). 
The high α-syn expression in the AcbC of AA rats coincided with increased peak DA 
overflow and faster re-uptake after stimulated release in comparison to the situation in the 
ANA rats. Methodological restrictions do not allow to conduct any direct correlations 
between α-syn expression and parameters of DA overflow, but the current results suggest 
that in a physiological environment the moderately increased α-syn expression leads to 
inhibition of DA release and facilitation of re-uptake. However, the differences in DA 
overflow between ANA and AA rats can be seen as contradictory to earlier results showing 
identical resting DA levels in the AcbC of these rats (Kiianmaa et al., 1995). This may be 
explained by the different firing rates of dopaminergic neurons between ANA and AA rats, 
since it has been reported that in other rodent line pairs with differential ethanol 
preference, the intrinsic firing rates of dopaminergic neurons in the SN and VTA tend to be 
higher in ethanol preferring animals in comparison to their ethanol avoiding counterparts 
(Risinger et al., 1994; Morzorati and Marunde, 2006; Beckstead and Phillips, 2008). The 
higher firing rate might be able to compensate for the inhibition of release and facilitation of 
re-uptake in the AcbC of AA rats and make the extracellular DA level identical with that in 
ANA rats. At present, the intrinsic activity of dopaminergic neurons has not been studied 
in ANA and AA rats and it would make a very interesting and important topic for future 
work. The reduced DA overflow in AA rats is unlikely to result from autoregulation by pre-
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synaptic D2 receptors, since their levels are lower in AA rats in comparison to ANA rats 
(Kiianmaa et al., 1991). 
Stimulated DA overflow in the AcbSh did not differ between ANA and AA rats after 
ethanol challenge (study I, Fig. 3) which concurs with previous data on extracellular DA 
levels after an ethanol challenge (Kiianmaa et al., 1995). In fact, the ethanol challenge 
evoked rather mild changes in DA overflow in comparison to the results reported by 
Budygin et al. (2001) which showed that ethanol causes a dramatic dose dependent 
reduction in stimulated DA release (but did not affect re-uptake) in the CPu of Sprague-
Dawley rats. The discrepancy could be explained by anesthesia used in the experiment 
setup, as Budygin et al. measured stimulated DA overflow in non-anesthesized, freely-
moving animals. Similar studies performed in mice have revealed that effects of ethanol on 
stimulated DA overflow were clearer in freely moving mice than in chloral hydrate 
anesthesized mice (Jones et al., 2006). In study I, the rats were anesthesized with urethane 
which induces a long-lasting surgical anesthesia, deeper than that achieved with chloral 
hydrate (Maggi and Meli, 1986; Lu and Greco, 2006). Thus, the results are in line with the 
general consensus that the effects of ethanol on the dopaminergic system are indirect and 
require fully functional connections to other neurotransmitter systems (see section 2.2.5) 
which can be severely affected by the applied anesthetics (Lu and Greco, 2006; Dalo and 
Hackman, 2013). 
6.2 LACK OF α-SYN MODULATES FUNCTION OF THE NEUROMUSCULAR 
JUNCTION BUT DOES NOT AFFECT MOTOR CONTROL (STUDY II) 
α-Syn is localized to peripheral and motor neurons in its native and pathological forms 
(Papachroni et al., 2005; Mu et al., 2013). The absence of α-syn does not affect the viability of 
peripheral neurons (Papachroni et al., 2005) but α-syn’s role in their function is unknown. 
In order to study the role of α-syn in lower motor neurons, electromyography and 
behavioral testing were performed in α-syn deficient and wild-type mice in the second part 
of this work (study II). The applied electrical stimulation produced R-CMAPs almost 
exclusively in the α-syn deficient mice (Fig. 10 B). The R-CMAPs can be of synaptic or 
neural origin (van Dijk et al., 1996). Synaptic R-CMAPs originate from an excessive 
acetylcholine effect in the synaptic cleft, whereas neural R-CMAPs are attributable to 
abnormal motor axons that generate impulse trains in the wake of a single passing impulse. 
In humans, synaptic R-CMAPs have typically one or two late components and the shape of 
the components is very regular, which fits quite well to the current findings (Fig. 10 A and 
B). Neural R-CMAPs are more irregular in shape and have up to 25 components. This 
suggests that α-syn may have a regulatory effect on the cholinergic tone at the 
neuromuscular junction. The regulation may occur at the level of vesicle pool organization 
(Nemani et al., 2010) or acetylcholine synthesis (section 2.2.1). However, other explanations 
for the R-CMAPS cannot be excluded; acetylcholinesterase terminates the signaling at the 
neuromuscular junction by breaking down the neurotransmitter into acetyl and choline 
groups, and acetylcholinesterase inhibitors can cause synaptic R-CMAPs (van Dijk et al., 
1996). Synaptic R-CMAPs have been detected also in a mouse-model of slow-channel 
syndrome where they are caused by slow closing of the Na+/K+ channels in the muscular 
acetylcholine receptors (Gomez et al., 1997). This is interesting because α-syn has been 
reported to be localized to the post-synaptic side of the neuromuscular junction in human 
skeletal muscle fibers (Askanas et al., 2000). 
Despite the pathological electromyography finding in the α-syn deficient mice, no 
significant differences were seen between the mouse lines in grip strength or ambulation 
(study II, Fig. 2 B and table 1). Even the initial difference detected in the Rotarod test 
appeared to be more because of a defect in motor learning and not in motor function (Fig. 
10 C). This is understandable since the effect of α-syn deficiency on the CMAPs did not 
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manifest itself consistently in all stimulation sets, indicating that the effect of α-syn in the 
neuromuscular junction is rather mild. However, other explanations for the differeces seen 
in the Rotarod test cannot be completely ruled out. It is possible that the hyperactivity 
detected in double (Senior et al., 2008) and triple knockout mice (Anwar et al., 2011) could 
contribute to the results. Deteriorated motor learning in α-syn deficient mice is still an 
interesting possibility, since overexpression of mouse α-syn has been reported to have a 
similar effect in young mice (Rieker et al., 2011). This suggests that a certain, controlled level 
of α-syn expression is required for optimal synaptic function and efficient motor learning 
(see section 2.2.8), and that these might be interfered by α-syn targeting therapies. The 
behavioral consequences of α-syn modulating therapies are difficult to predict since a 
complete lack of α-syn can have the same behavioral effect as a modest, local increase in the 
protein level, as shown by the increased ethanol preference in knockout mice (study I and 
Liang et al., 2003 vs. López-Jiménez et al., 2013). 
6.3 LACK OF α-SYN HAS NO EFFECT ON CORTICAL SPREADING 
DEPRESSION (STUDY III) 
Since α-syn modulates glutamatergic neurotransmission (Liu et al. 2004), facilitates calcium 
influx (Hettiarachchi et al., 2009; Martin et al., 2012) and is highly expressed in the cortex 
(Iwai et al., 1995) it was postulated that there might be differences in the initiation and/or 
propagation of CSD between wild-type and α-syn deficient mice (study III). However, no 
differences were seen between the mice (Fig. 11). Initiation and propagation of CSD reflect 
neuronal excitability (Eikermann-Haerter et al., 2012), and the current results suggest that 
facilitation of neuronal excitability is not part of the native physiological function of α-syn. 
Some functions of α-syn can be masked in knockout mice by the other synucleins, 
especially -syn (see section 2.1.1), but according to Adamczyk and Strosznajder (2006) -
syn is not able to influence calcium influx significantly. However, it still remains possible 
that oligomeric forms of the protein can affect excitability in a pathological manner 
(Diogenes et al., 2012, Martin et al., 2012). CSD causes massive glutamate release, but the 
mechanisms of release in CSD appear to include also the reversal of glutamate transporter 
function (Basarsky et al., 1999; Charles and Brennan, 2009). The current results support the 
idea that α-syn modulates particularly pre-synaptic mechanisms of vesicular 
neurotransmitter release (Sidhu et al., 2004), but the modulation is so subtle that it is unable 
to affect a phenomenon as strong as CSD which includes complete neuronal depolarization 
and alternative mechanisms of neurotransmitter release. 
CSD is a pathological phenomenon and considered as the electrophysiological 
manifestation of the migraine aura (Charles and Brennan, 2009; Dreier, 2011). It has been 
long debated whether CSD is a cause or a consequence of a migraine attack, but the current 
opinion is that it triggers the migraine headache (Eikermann-Haerter et al., 2012). One 
peculiar feature of migraine is the accumulation of iron into the basal ganglia (Welch et al., 
2001; Kruit et al., 2009). Since iron is able to promote α-syn expression (Febbraro et al., 2012) 
and aggregation (Uversky et al., 2001), and iron accumulation is a feature of 
synucleopathies (Dusek and Schneider, 2012; Mochizuki and Yasuda, 2012) there might be 
some connection between migraine and synucleopathies. The first case-control study 
published on this topic indicated that male PD patients have an increased prevalence of 
moderate to severe migraine (Lorentz, 1989). In contrast to these results, van Hilten (1992) 
reported a preliminary finding from 5 PD patients suggesting that onset of PD seemed to 
alleviate migraine, especially in patients with no family history of migraine. Similar 
observations were made by Barbanti et al., (2000) from a larger set of patients, but their 
interpretation of data has been subjected to criticism (Serrano-Duenas, 2001). Since D2 
antagonists are capable of alleviating migraine (Snow et al., 2002) PD therapy may easily 
obscure the results on migraine prevalence. The current results suggest that if there is any 
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causality between migraine and PD, brain α-syn is not the connecting factor, and that α-syn 
targeting therapies will not necessarily increase migraine vulnerability. Changes in the 
peripheral sympathetic nervous system in migraine, such as reduced plasma noradrenaline 
and increased sensitivity of peripheral adrenergic receptors, indicate that common factors 
with PD are more likely to be found in the periphery (Peroutka, 2004; Orimo et al., 2007). 
6.4 EXOGENOUS α-SYN AFFECTS STIMULATED DOPAMINE OVERFLOW 
(STUDY IV) 
According to the pathological protein transfer theory different forms of α-syn are 
exocytosed and taken up by neighbouring cells (Luk et al., 2012). In an attempt to study the 
effects of exogenous monomeric α-syn on DA release and re-uptake processes, recombinant 
human α-syn was injected into the DS of wild-type and α-syn deficient mice, and 
stimulated DA overflow was measured six days later and immediately after the 
microinjection (study IV). The injected α-syn was not detected from the striatum six days 
after microinjection, which might be due to degradation (Webb et al., 2003) or slow axonal 
transport to the cell perikaryon (Utton et al., 2005; Volpicelli-Daley et al., 2011). The inability 
to determine the fate of the injected α-syn between the two possibilities is a limitation of 
this present study. Nevertheless, the injection of exogenous α-syn caused a reduction in 
peak DA overflow induced by 50 Hz stimulations, detectable selectively only in the α-syn 
deficient mice (Fig. 12 G and H). A reduction in the maximal velocity of DA re-uptake was 
detected also in wild-type mice, even though the effect was more robust in the α-syn 
deficient mice (Fig. 12 I and J).  
The effects of the α-syn microinjection did not localize to the exact site of the 
microinjection, but as shown by the stained cells in Fig. 12 E and F, the injected protein can 
diffuse quite distant from the injection site. The delayed effects of human α-syn 
microinjection on stimulated DA overflow in mice were similar to those of human α-syn 
overexpression in rats induced by viral vectors (Gaugler et al., 2012, Lundblad et al., 2012). 
The effects of the overexpression were partly due to axonal degeneration and neuronal loss 
in the nigrostriatal dopaminergic system, but the reduction in TH activity, DA release and 
re-uptake manifested even before the neurodegeneration (10 days after vector injection; 
Lundblad et al., 2012) and the magnitude of these changes exceeded that of the neuronal 
loss (Gaugler et al., 2012). Therefore human α-syn has also functional effects on the 
dopaminergic neurons, and since the changes in stimulated DA overflow were similar in 
the current study, it appears that also exogenous, injected α-syn can have the same effects. 
Stimulated DA release can be affected by reduced activity of TH and VMAT2 (section 2.2.1, 
Fig. 3), and α-syn is known to inhibit not only the function but also the expression of both 
proteins (Yu et al., 2004; Guo et al., 2008). The changes in activity that arise from the 
expression of the proteins may linger long after α-syn itself has been removed from the 
system. 
The immediate effects of α-syn did not include a reduction in peak DA overflow, but 
instead there was a trend towards increased DA overflow, manifesting especially with the 
low-frequency stimulations (Fig. 13 A-D). Considering the dynamic and modifiable 
structure of α-syn (section 2.1.2), multiple and even opposing mechanisms of action of the 
protein are feasible (Sidhu et al., 2004). Previously published results suggest that there are 
three explanations for the increase in DA release: 1) The slightly reduced affinity of the 
DAT (described by the Km value; Fig. 13 G) causes the increase in peak DA overflow 
(Wightman and Zimmerman, 1990; see also section 2.2.4). 2) The striatal cells that take up 
α-syn (Fig. 13 F) are cholinergic interneurons, and α-syn affects their output which in turn 
affects the release of DA (Rice and Cragg, 2004; Section 2.2.5). 3) Exogenous α-syn facilitates 
the assembly of the SNARE-complex at the terminal membrane, which translates into 
increased DA release (Burre et al., 2010; Section 2.2.3).  
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The credibility of the first explanation is hampered by the increase in maximal velocity of 
DA re-uptake (Fig. 13 H), showing that even if affinity of DAT were to be reduced, it still 
could be compensated by increased membrane expression of the protein. The second 
explanation is plausible but uncertain since the exact nature of the stained cells remains 
unknown. Their characterization remains a necessary and interesting topic for future work. 
The problem with the third explanation is that all studies done in catecholaminergic models 
indicate that α-syn inhibits SNARE complex assembly or reduces DA release through other 
mechanisms (Larsen et al., 2006; Darios et al., 2010; Choi et al., 2013). There are some results 
from glutamatergic regions that suggest that α-syn could promote neurotransmitter release 
(Cabin et al., 2002, Liu et al. 2004; Gureviciene et al. 2007), and the primary neurons which 
were used by Burre et al. (2010; 2012) for studying the SNARE-complex assembly were 
obtained from mainly glutamatergic areas (cortex, hippocampus) of mouse and rat brain. 
Similar studies by Chandra et al. (2005) were performed using whole-brain samples, and 
glutamate is by far the most abundant neurotransmitter in the brain (Bear et al., 2007; 
Nestler et al., 2009). It has been shown that α-syn binds to intracellular, catecholaminergic 
markers such as TH (Perez et al., 2002) and VMAT2 (Guo et al., 2008) which are not present 
in glutamatergic neurons. The facilitation of release appeared to be mild and transient 
(immediate vs. delayed effects) and it might be that the exogenous protein slowly 
incorporates itself with the catecholaminergic markers and microtubules (Alim et al., 2004) 
at the striatal dopaminergic terminals, and loses the association with the SNARE-
complexes. It might be that if catecholaminergic markers are absent from the pre-synaptic 
terminal, α-syn is available for facilitation of the SNARE-complex assembly. 
The delayed (Fig. 12 I and J) and immediate (Fig. 13 H) effects of exogenous α-syn on 
maximal velocity of DA re-uptake were also quite opposite. The results on the immediate 
effects of the protein suggest that α-syn can speed up DA re-uptake also in a physiological 
environment (Lee et al., 2001; Fountaine et al., 2008). This mechanism of function is 
supported by the results of study I where an endogenous increase of α-syn expression was 
associated with more efficient re-uptake (Fig. 9 B and C). Considering the role of α-syn as a 
negative regulator of DA release (Abeliovich et al., 2000; Lundblad et al., 2012), facilitation 
of DA re-uptake is a very logical function for the protein, since both functions reduce the 
concentration of the neurotransmitter at the synaptic cleft.  
The delayed effects of α-syn microinjection showed that exogenous α-syn is also able to 
reduce the maximal velocity of DA re-uptake (Fig. 12 I and J; Wersinger and Sidhu, 2005) 
but the results of Lundblad et al. (2012) and Bellucci et al. (2011) suggest that this function is 
associated with neurodegeneration and aggregation of α-syn. The exogenous α-syn may 
reduce the rate of re-uptake not only by binding DAT to the intracellular compartment 
(Wersinger et al., 2005; Bellucci et al. 2011), but it is also capable of causing inflammation 
(Lee et al., 2010) which may interfere with the re-uptake process (L’episcopo et al., 2010). It 
appears that human α-syn is particularly toxic to the rodent brain and causes severe 
degeneration within a few weeks (Lundblad et al., 2012), whereas significantly higher 
overexpression of mouse α-syn in mouse brain is tolerated for several months (Rieker et al., 
2011). Luk et al. (2012) were able to initiate neurodegeneration with pre-formed mouse α-
syn fibrils three months after exposure, but injection of monomeric mouse α-syn had no 
degenerative effects at any of the tested time points up to five months. Taken together, the 
results suggest that exocytosed α-syn can affect DA release and re-uptake, but it remains 
uncertain whether the effect is pathological or a part of normal control of synaptic 
signaling. 
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7 Conclusions and Summary 
The general aim of this thesis work was to clarify the neuromodulatory effects by which α-
syn could affect synaptic signaling under different scenarios. Based on the results, the 
following conclusions can be drawn: 
1) The ethanol-preferring AA rats have a higher expression of α-syn in AcbC than their 
non-preferring ANA counterparts. They also display lower maximal DA overflow and 
faster re-uptake in response to stimulation of the dopaminergic axons in the same region of 
the striatum. This suggests that there is a link between differential α-syn expression, 
dopaminergic neurotransmission and genetic predisposition to drug abuse and alcoholism. 
It also appears that ethanol does not modulate pre-synaptic mechanisms of DA signaling 
directly. 
2) The lack of α-syn in mice can result in dysregulation of cholinergic signaling at the 
neuromuscular junction, but there is no definite evidence that it could significantly affect 
the motor performance of these animals. However, lack of α-syn does appear to impair 
motor learning. 
3) Lack of α-syn does not affect the initiation or propagation of CSD, suggesting that the 
native function of α-syn does not include facilitation of neuronal excitability. 
4) Locally applied exogenous human a-syn affects DA overflow, and the effects depend on 
the presence of endogenous a-syn. 
Taken together, it can be concluded that α-syn can affect dopamine release and re-uptake in 
striatum with various mechanisms that can oppose each other, but in the normal 
physiological environment and level of expression, the net outcome of the effects is reduced 
release and accelerated re-uptake. Elevated expression of the protein in specific areas of the 
reward circuitry of the brain may function as a predisposing factor to drug and ethanol 
abuse, as shown by the high expression of α-syn in the AcbC of AA rats associated with 
decreased peak DA overflow and facilitation of DA re-uptake. Even though α-syn can 
modulate such behaviors as ethanol preference or motor learning, the protein’s role is only 
to fine-tune neurotransmitter signaling, as the slight modulation of the neuromuscular 
junction in skeletal muscles yields little effect on motor performance and α-syn is unable to 
influence a phenomenon as strong as CSD which produces massive depolarization in the 
cortex. 
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Alpha-synuclein is a small 
pre-synaptic protein, best known for 
its aggregation into Lewy bodies in 
Parkinson’s disease, but it is also 
up-regulated in addiction. This 
thesis examined how alpha-
synuclein influences synaptic 
signalling. It appears that the 
main physiological function of 
alpha-synuclein is to regulate 
dopamine signalling in the brain. 
At the behavioral level, the synaptic 
modulation by alpha-synuclein can 
affect functions such as preference 
for substances of abuse and motor 
learning.
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